1

2

3

CONTENTSPresident’s Message 4

Faculty Research 10

Student Research 30

Financial Report 40

Scholarly Activity Report 42

Editor Gil Chorbajian

Contributing Writers David E. Goldschmidt / Patrick Rathbun

Contributing Photographers Scott Barrow / Kris Qua

Design Jen Danchetz, D|2 Design Defined

4

The major goal of our Strategic Plan is to promote excellence in teaching and research, which to-gether contribute to our educational preeminence in pharmacy, pharmaceutical sciences, and the health sciences.

The focus of this publication is on the dynamic research activities taking place at the College. Our investments in research – highlighted by the recruitment of outstanding faculty, expansion of available research space, acquisition of new laboratory equipment, and the opening of the Pharmaceutical Research Institute – have set us apart from many other colleges.

The results of these efforts led to $10 million in research funding in 2010, a figure that we reached two years sooner than planned. Our research ac-complishments have also led to enhanced prestige for the College and helped further distinguish ACPHS among our peer schools.

Without question, the greatest beneficiaries of our expanded research program are the students. At many colleges and universities, research activities are largely the domain of post doctoral students

and graduate students. At ACPHS, we strongly encourage our undergraduate students to engage in research while on campus, and they are in-creasingly seeking out these opportunities.

From helping design experiments to evaluating the results, our students are not just acquiring knowledge, but they are participating in the dis-covery process. Along the way, they are learning “how to think,” an invaluable skill that will help them stand out when they compete for residen-cies, fellowships, graduate school, and post-grad-uate employment.

This Report highlights the accomplishments of several student researchers. One such individual is Jessica Phelps, a fourth year student in the B.S. program in Pharmaceutical Sciences. Jessica is working with Dr. Luciana Lopes on the devel-opment of a gel that would be injected under the skin to help improve treatment for patients suffering from addiction. Fifth year Pharm.D. student Michael Camuso has teamed with Dr. Richard Dearborn to tackle another major health threat – cancer. Michael is assisting Dr. Dearborn in exploring ways to control a regulatory protein

President’s Ledger(VDUP1) that may play a key role in slowing or even stopping the growth of cancer cells. Graduate student Zhanbin Wang is working in the lab of Dr. Stefan Balaz on our Vermont Campus to develop an approach for modeling how chemicals are transported and accumulate in biological membranes (see image on page 5). Their work will help researchers predict how new drug candidates are likely to behave in the body, even before making a compound.

Unfortunately, all of the research taking place across our two campuses cannot fit onto these pages, but the investigators highlighted here dem-onstrate the breadth and depth of the expertise that exists at the College today.

As you read further, you will learn about: Dr. Karen Glass, who received a grant from the American Heart Association that is reserved for “promising beginning scientists;” Dr. Arnold Johnson, who was awarded a prestigious $1.4 million NIH grant; Dr. Darius Mason, who has quickly become a strong contributor to our nephrology pharmacy group; Dr. Amit Pai, who is rethinking traditional approaches to dosing drugs; and Dr. Alexandre Steiner, who is ques-tioning long held beliefs about the treatment of severely septic patients.

This year marks the 130th anniversary of the College’s founding, and while that is a cause for some reflection, our sights continue to be set on the future — a future where research will continue to play an important role in helping us realize our full potential as an institution.

James J. Gozzo, Ph.D.President Albany College of Pharmacy and Health Sciences

5

Stefan Balaz, Ph.D., Chair and Professor of Pharmaceutical Sciences at the ACPHS-Vermont Campus, has a $1.35 million NIH grant to develop models like the one above to help predict the behavior of new drug candidates. Dr. Balaz and his team, which includes students such as Zhanbin Wang (see page 36), hope their research will help decrease the time-to-market for new drugs as well as the costs associated with research and development. The above image shows Mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2) bound with its inhibitor (PDB code 3KGA). This protein serves as a potential target for several inflammatory disorders. The color of the protein surface indicates its electrostatic potential [from red (most positive) to purple (most negative)]. Crystal waters are shown as red balls.

6

7

8

ACPHS has more than 25,000 square feet dedicated to research.

Pharmaceutical Research InstituteRensselaer, NY

Vermont Campus Colchester, VT

9

Bioscience Research Building (BRB) Albany, NY

10

If you want a lesson in successful multitasking brought to the extreme, look no further than Pharmaceutical Research Institute (PRI) Executive Vice President and Chairman, Shaker A. Mousa, Ph.D., MBA, FACC, FACB. Dr. Mousa is a tireless leader at PRI, the College’s drug discovery and development institute which is located in Rensselaer, New York. He also serves as a tenured professor in the Department of Pharmaceutical Sciences at Albany College of Pharmacy and Health Sciences. In addition, Dr. Mousa holds numerous academic appoint-ments at universities and research centers throughout the world.

A native of Alexandria, Egypt, Dr. Mousa’s impressive curriculum vitae includes more than

600 publications (a number that’s growing even as you read this), 30 U.S. patents, over 200 foreign patents, and numerous contributions to the dis-covery and development of a variety of pharma-ceutical products, including clinical candidates for breast cancer detection, noninvasive imaging agents, and other treatment-based drugs.

To add to these accolades, Dr. Mousa was re-cently appointed to the position of Vice Provost for Research at the College. This key appoint-ment by President James J. Gozzo, Ph.D. perhaps comes as no surprise, as Dr. Mousa’s work has been instrumental in helping grow the Col-lege’s research program to one that is annually awarded millions of dollars through a variety of private and public sources, including the Na-

tional Institutes of Health and the U.S. Depart-ment of Defense.

“We have more than $10 million in active research grants, contracts, and awards,” says President Gozzo, “and we expect that figure to increase dramatically in the future.” Since his arrival at the College, President Gozzo has placed a strong emphasis on research by investing in state-of-the-art laboratory facilities, adding graduate degrees in key research areas, and renewing the focus on faculty-mentored research activities with students.

In his new role, Dr. Mousa plans to increase the emphasis on research at the College without detracting from the College’s current strengths.

Come Back to the Bench

Faculty Research

11

In short, he has called for the faculty to, in his words, “Come back to the bench.”

The Cycle of MentorshipLike President Gozzo, Dr. Mousa strongly be-lieves in the cycle of mentorship. And while the faculty-student mentoring model is impor-tant, Dr. Mousa sees much more. Combining the talents of senior and junior faculty members enables the senior faculty to act as mentors to the junior faculty, imparting in-depth knowledge and experience in areas such as teaching, re-search, and scholarship. This new research men-toring system will encourage senior and junior faculty members to come together to develop joint research proposals. “One of the greatest strengths we have is our ability to communicate and collaborate,” says Dr. Mousa. “We need to relearn the fact that one plus one does not equal two; it adds up to much much more.”

Without question, mentoring involves both undergraduate and graduate students. “Another important part of the mentorship cycle,” says Dr. Mousa, “is where our graduate students gener-ate preliminary data that our faculty can then develop into collaborative studies and grants.” Many of these graduate students, including those who study with Dr. Mousa, go on to careers in research of their own, be it in academia or at pharmaceutical research centers.

As they tackle their sixth-year rotations, a new group of four Pharm.D. students is assigned to Dr. Mousa every six weeks. From their first meeting, Dr. Mousa’s approach is to let students develop and explore their own ideas. “Our job is to show them the way,” he says, “and open doors yet unknown to these fresh minds. They do the rest.”

While publication helps any Pharm.D. graduate stand out amongst their peers, approximately one out of four of Dr. Mousa’s students finds that “spark” and goes on to graduate work pursuing a Ph.D. or lands a residency in a phar-maceutical research company. Not surprisingly, Dr. Mousa previously worked for seventeen years as a principal research scientist at DuPont Pharmaceuticals Co.

Pathways to CollaborationAnother key component to Dr. Mousa’s vision for mentoring is what he calls “joint intramural applications.” With so much good research going on at the College, Dr. Mousa sees a need to form pathways of communication and col-laboration between separate departments and current “silos of research.” One of the joys he has experienced in his short tenure thus far as Vice Provost for Research is feeling the excitement amongst faculty members when such a pathway or bridge is revealed.

“Strong research often involves the combination of seemingly disparate ideas,” says Dr. Mousa. “So in my new role, going along with the idea that one plus one is much more than two, I am looking for ways to bring together researchers from different fields.” This also goes beyond just the College, as strong research certainly requires collaboration and work from multiple entities across the globe, which in turn opens more doors for students at the College.

To encourage this crosspollination and entice faculty to “come back to the bench,” Dr. Mousa

organized the inaugural ACPHS Research Forum in January 2011. This well-attended all-day event brought researchers from many different departments and programs, including the satellite Vermont campus, which opened in 2009. The day, which began with introductory remarks from President Gozzo and Provost and Dean Mehdi Boroujerdi, featured presentations highlighting research projects from across the College. The event was organized by Dr. Mousa in a deliberate attempt at opening collaborative pathways between departments, a strategic move that has already started generating positive feed-back from faculty. Rounding out the day were poster sessions by faculty and graduate students, plus a set of closing remarks by Dr. Mousa him-self, reiterating the message of collaboration and the cycle of mentorship.

“By establishing this synergistic event,” says Dr. Mousa, “we showed that quality science matters, that we can solve those problems that ultimately result in the treatment of disease and improve-ment in human health.” In other words, the aim is to derive clinical value out of a variety of research efforts. And while his own experi-ences in doing exactly this have proven to be very effective, he also views himself as a team builder, especially in his new role as Vice Provost for Research.

“There are no boundaries in science,” he says. “Our goal as scientists is to solve problems and bring value to all of humanity from our efforts. Otherwise, science means nothing.”

“Our goal as scientists is to solve problems and bring value to all of humanity from our efforts. Otherwise, science means nothing.”

12

“I Hate Routine”“There are unfortunately only twenty-four hours in a day,” says Dr. Mousa, acknowledging the difficulties many faculty members face in execut-ing their research. Faculty research efforts often are overlooked or demoted to a lower priority as faculty aim to balance teaching loads, commit-tee involvement, and other duties that are crucial to the ongoing success of the College and its graduates.

“I hate routine,” says Dr. Mousa, “as do many fac-ulty and those doing research.” Part of his vision is to provide both the physical and human resources to support faculty in their research. “We need more highly skilled tech staff members and post-docs to do the groundwork in support of faculty research. We also need core facilities where such execution can be that much more efficient.”

As a result of supplying such mechanics for the research process, Dr. Mousa believes fac-ulty workloads will be freed up, thus providing faculty more time to interpret their research data, develop grant proposals, publish their results, and act as mentors in their respective fields. “Another part of this grand equation,” says Dr. Mousa, “is providing faculty with knowledgeable grant writ-ers, again in an effort to free up their time to focus on the core aspects of their research.”

Dr. Mousa believes that graduating top-notch students is certainly a priority of the College, but asks, “What differentiates these graduates? How can the Pharm.D. we offer be stronger than the norm?”

Not surprisingly, he turns to research and the concept of mentorship for answers. “Strategi-cally, we need to raise the bar in the pharmaceu-tical research community,” he says. “If we build a

state-of-the-art research community here, it will serve as a model to other colleges and research organizations, and set us and our graduates above the rest.” One model worth duplicating is that of the PRI facilities.

“I also like measurements and equations,” says Dr. Mousa. And a little competition doesn’t hurt, either. Another key aspect of Dr. Mousa’s vision for research at the College is an annual award for the best research. More specifically, he envi-sions a formula that sums weighted measures of acquired funding, publication, graduate student mentorship, junior faculty mentorship, and other factors. “We want to encourage so many differ-ent yet important things here,” says Dr. Mousa, “so let’s put them all together into a formula and reward those among us who are leading the way.”

Through all of his efforts, Dr. Mousa hopes to convince faculty members at the College to “come back to the bench.”

Making a DifferenceAs to what drives his efforts and his own research, Dr. Mousa states, “I want to make a difference.”

Dr. Mousa was brought to the College in 2003 by President Gozzo to launch the Pharmaceutical Research Institute. Three years later, experienc-ing dramatic growth, PRI expanded to its current location in the Center for Nanopharmaceutical Technology in the University at Albany’s East Campus in Rensselaer, New York.

The primary objective of PRI is to enrich phar-maceutical education at the College by providing hands-on access to the full drug development lifecycle. Through Dr. Mousa’s leadership, PRI conducts pre-clinical testing and clinical trials to develop drugs for transitioning to industrial manufacture. Very much a multifaceted entity,

a key aim of PRI is to introduce innovative noninvasive techniques for diagnosing vascular, oncological, and neurological disorders. Part of this innovation includes nanotechnology.

“Nanotechnology is a new tool,” says Dr. Mousa. “With it, we are able to deliver more focused and exacting doses of a wide array of drug treat-ments, including techniques for early detection of cancers.” The promise of such nanophar-maceutical technologies is to avoid some of the other detrimental or even dangerous side effects of traditionally administered drugs.

With the multitude of ongoing research at PRI, Dr. Mousa is quick to identify a current passion in his own research—helping those with pan-creatic cancer. “There’s a feeling of helplessness amongst patients and their families—and their oncologists,” he says, noting that many of the on-cologists on the front lines of pancreatic cancer need psychotherapy to deal with the constant loss of patients after such a short time span, on average three months.

“We’re on the verge of clinical trials for a drug that shrinks the tumor in which the pancreatic cancer cells reside,” describes Dr. Mousa. “We starve it. If we can prevent it from spreading throughout the body, we have effectively bought enough time for a surgeon to operate and remove the tumor.”

At the end of his seemingly superhuman work-days, Dr. Mousa’s personal aims keep him from giving up. “We cannot quit. We have to keep trying. Every day, I wish to alleviate the suffering of human beings in the face of disease.”

“We cannot quit. We have to keep trying.”

13

14

15

Darius L. Mason Assistant Professor, Dept. of Pharmacy Practice

Darius L. Mason, Pharm.D., BCPS, has been awarded a grant from the Genzyme Corporation in the amount of $187,863 to study the effects of different phosphate binders on vascular calcifica-tion, inflammation and endothelial dysfunction in chronic kidney disease (CKD) patients.

CKD patients experience significant morbidity and mortality from heart disease. Several fac-tors contribute to incidences of heart disease in these patients, including high levels of phos-phorus. High levels of phosphorus can lead to calcification, or hardening, of the blood vessels. The calcification process begins in the early stages of disease and continually progresses as kidney function declines. Additionally, CKD patients often have high levels of a substance called fibroblast growth factor-23 (FGF-23), a phosphorus excreting hormone, which has been related to heart disease. As kidney function declines, less phosphorus is excreted and more FGF-23 is released.

Phosphate binding medicines are used to lower the amount of phosphorus absorbed. Recent evidence has suggested that use of phosphate binder therapy in the non-dialysis popula-tion lowers concentrations of FGF-23, a more sensitive regulator of mineral metabolism

than phosphorus, associated both with vessel calcification and mortality. However, initiating phosphate binder therapy in the early stages of CKD to reduce or slow the progression of vas-cular calcification has not fully been explored. Furthermore, lowering FGF-23 levels in CKD patients may also lower substances in the blood that cause hardening of blood vessels and blood vessel inflammation in the CKD population.

Dr. Mason and his co-investigators’ research is designed to determine if using the phosphate binders in the earlier stages of kidney disease (before dialysis) can decrease FGF-23 levels and biomarkers that are associated with hardening of the blood vessels and heart disease. This col-laborative research project includes the support of faculty at ACPHS who are experts in kidney disease (Dr. Amy Barton Pai) and drug devel-opment (Dr. Shaker Mousa) in addition to the assistance of Albany Medical Center physician Dr. George Eisele. Clinically important modi-fications of biomarkers of vascular calcification, inflammation and vessel health after treatment with phosphate binders may indicate a reduc-tion in the progression of blood vessel calcifica-tion and suggest a heart benefit in the non-dialysis CKD population.

Faculty Research

16

Arnold Johnson Professor, Dept. of Pharmaceutical Sciences

Arnold Johnson, Ph.D., has been awarded a grant from the National Institutes of Health in the amount of $1.4 million. Dr. Johnson will study the role of glycogen synthase kinase 3β in tumor necrosis factor induced lung injury.

Acute Respiratory Distress Syndrome (ARDS) is a common (150,000 cases/year in the U.S.) and costly disorder with a mortality rate of approximately 50%. During ARDS, the lung has a change in blood pressure and the blood vessels become leaky which allow the lung to fill with fluid (also known as edema). The “wet lung” cannot ventilate adequately which decreases oxygen in the blood and increases carbon dioxide in the blood.

Sepsis, commonly known as blood poisoning, is a major factor predisposing to ARDS. Sepsis affects approximately 250,000 Americans each year. The average death rate for sepsis is 40%.Combat-associated trauma with sepsis is a particularly timely concern due to ongoing operations in Iraq and Afghanistan.

ARDS is mediated, at least in part, by Tumor Necrosis Factor. TNF is a protein that can cause

symptoms common to sepsis. TNF is released by white blood cells in response to infection. TNF causes the blood vessels to become leaky similar to what happens in ARDS. An enzyme called glycogen synthase kinase 3β can mediate some of the TNF response.

The strategy for this study is focused on glyco-gen synthase kinase 3β which might modify this lung-injury response during sepsis. Successful completion of the proposed studies may result in progress in the treatment and prevention of advanced sepsis/ARDS.

An increasing older population with co-existing conditions such as depression of the immune system combined with an increasing population of antibiotic resistant bacteria will increase the risks of sepsis. The understanding of the lung response to various disease states could lead to therapeutic advances in humans, resulting in improved cell function, fewer incidences of lung injury, and ultimately, better outcomes for patients who develop sepsis.

Faculty Research

17

Arnold Johnson Professor, Dept. of Pharmaceutical Sciences

17

1818

19

Karen C. GlassAssistant Professor, Dept. of Pharmaceutical Sciences

Karen Glass, Ph.D., a newly appointed Assis-tant Professor in the Pharmaceutical Sciences Department on the Vermont Campus, has been awarded a Beginning Grant-in-Aid from the American Heart Association. This grant for $132,000 will fund Glass over the next two years to study the role of PHD finger modules in heart disease.

Cardiovascular disorders, such as infarction and hypertension, place undue stress on the heart muscle often resulting in cardiomyocyte hypertrophy, or an enlarged heart. Due to the increased size of heart cells, which are unable to divide after birth, pathologic cardiac hypertrophy significantly weakens the heart leading to higher morbidity and mortality rates associated with progressive heart failure. In order to contribute to the search for an ef-fective therapeutic treatment for the prevention

of hypertrophic growth, Dr. Glass is trying to identify common signaling pathways involved in the development of heart disease.

PHD fingers are important protein motifs found in a variety of cardiac genes, whose disruption affects cardiac muscle fiber develop-ment and leads to heart disease. The results generated by this study will provide a comprehensive view of the structural and molecular mechanisms by which PHD- containing proteins regulate gene expression in cardiac muscle development and disease. A deeper understanding of how these molecu-lar signaling pathways can be modulated will provide insight into the design of new therapeutic strategies, and may help to identify novel diagnostic markers and targets to prevent and treat cardiovascular disease.

Faculty Research

20

Faculty Research

Manjunath (Amit) P. Pai Associate Professor, Dept. of Pharmacy Practice

Amit Pai, Pharm.D., received a grant from the National Kidney Foundation of Northeast New York in the amount of $29,996. Pai will study whether the risk of drug induced kidney injury can be reduced in obese patients.

Twenty million Americans are thought to have chronic kidney disease, which is associ-ated with significant morbidity, mortality, and high treatment costs. Although the cause of chronic kidney disease is multifactorial, the increasing number of patients with this condition is thought to be a result of increas-ing rates of obesity and diabetes in the United States. The progression of mild chronic kidney disease to a more severe form can be accelerated by acute kidney injury. Several FDA approved drugs that are currently on the market can have the unintended side effect of

inducing acute kidney injury. The risk of this side effect may be increased if unnecessarily high doses of the drug are used. This poten-tial risk is especially important for drugs that are dosed based on the patient’s body weight. Dosing patients on actual body weight may lead to estimation of unnecessarily high doses that can then increase the risk of acute kidney injury. This potential error may be even worse in patients who are obese. Given that one in three Americans is now classified as obese, it is imperative that we understand how to dose drugs better in this population.

Dr. Pai and his co-investigators will be studying the pharmacokinetics and risk of acute kidney injury with the antibiotic agent, gentamicin, in an animal model of obesity. This collaborative research project includes the

support of faculty at ACPHS who are experts in toxicology (Dr. Hassan El-Fawal), drug development (Dr. Shaker Mousa) and ad-vanced pharmacokinetic modeling (Dr. Thomas Lodise).

The current method used to detect acute kidney injury is not very sensitive. As a result, Dr. Pai’s group is studying new biomarkers of acute kidney injury to identify more sensitive methods of detection. These data will then be used to identify an approach to dosing gentamicin that maintains effective concentra-tions while reducing the risk of acute kidney injury. If this model is successful, the ap-proach developed by Dr. Pai’s group can then be used to improve dosing of other drugs used by obese patients.

21

2222

23

Faculty Research

Alexandre A. SteinerAssistant Professor, Dept. of Pharmaceutical Sciences

The American Heart Association awarded a grant in the amount of $308,000 to Alexan-dre A. Steiner, Pharm.D., Ph.D., to study the benefit of naturally occurring hypothermia in patients with septic shock.

The systemic inflammatory response syn-drome (SIRS) is a serious complication in hospitalized patients. It is commonly caused by infection, in which case it is named sepsis. This malady is associated with unacceptably high mortality rates, which may be as high as 70% in those patients who develop circulatory shock. At least 750,000 cases of sepsis occur annually in the USA and account for more than $16 billion in healthcare expenses.

As traditional anti-inflammatory therapy shows little efficacy in septic patients, it be-comes evident that the outcome of sepsis relies largely on the host’s own defense strategies. Whereas the fever (elevation in body temperature) that develops in the over-whelming majority of septic patients (90%) is considered a host-defense strategy, the hypothermia (fall in body temperature) that

occurs in some cases of SIRS/sepsis (10%) is a phenomenon that continues to puzzle physi-cians and scientists.

It is not uncommon for a septic patient who develops hypothermia to be re-warmed with the use of heating blankets. This practice, however, is not based on solid evidence show-ing that the hypothermia that occurs naturally in septic patients is detrimental. Preliminary studies by Dr. Steiner led to the hypothesis that, in the most severe cases of SIRS, naturally occurring hypothermia relieves the imbalance between oxygen supply and demand during cardio respiratory dysfunction and aids the host better than fever.

This project has strong clinical implications, as it will provide the foundation for possible clinical studies to evaluate whether septic patients with cardiovascular shock can benefit from naturally occurring hypothermia. The possibility exists that lives could be saved simply by not re-warming (at least not to a full extent) those septic-shock patients who become hypothermic.

24

“The great thing in this world is not so much where we stand, as in what direction we are moving.”

2525

“The great thing in this world is not so much where we stand, as in what direction we are moving.”

- Oliver Wendell Holmes

26

“Cut my arm and you’ll see green blood,” says Thomas P. Lodise, Pharm.D., Associate Profes-sor in the Department of Pharmacy Practice. He’s talking about that signature “midnight green” of his native Philadelphia Eagles, not the hunter green of the New York Jets—and certainly not the dark blue of the New York Giants. In his eighth year at Albany College of Pharmacy and Health Sciences, Dr. Lodise might not be rooting for any New York teams, but he’s quickly become an all-star in the field of epidemiology, studying antibiotic exposure-response relationships in patients.

His research goals are straightforward, though not that easily attained. First, improve patient outcomes through carefully crafted patient care strategies and antibiotic regimens. Second, certainly related to his first goal, reduce the likelihood of toxicity in patients that occurs as a result of the very same antibiotics designed to help fight infection. Third, somehow stay ahead of the game by minimizing the emergence of antibiotic resistance in future strains and meta-morphoses of bacterial infections.

In September 2008, Dr. Lodise received four grants totaling almost a half million dollars from three separate sources, including Cubist

Pharmaceuticals headquartered in Lexington, Massachusetts, pharmaceutical industry leader Pfizer, and the Foundation for Health Living in Buffalo, New York. Since joining the faculty at the College, he has been awarded over one mil-lion dollars in extramural funding as Principal Investigator or co-Principal Investigator—no easy task in today’s competitive and dwindling research funding marketplace.

Dr. Lodise’s 2008 grants were awarded to sup-port the study of methicillin-resistant staphy-lococcus aureus, better known as MRSA, a “serious public health concern” in the eyes of the National Institute of Health (NIH) that continues to demonstrate increased resis-tance to the antibiotics and other medications prescribed to treat it. In particular, Dr. Lodise is researching the efficacy of antibiotics versus potentially deadly MRSA infections, a rivalry going back to Dr. Lodise’s postgraduate fellow-ship in Infectious Diseases Pharmacotherapy and Outcomes at Wayne State University in Detroit, Michigan. “I learned how important it was to care for these patients on an individual-ized basis,” says Dr. Lodise. “In particular, I saw the need to personalize the dosing of antibiotics in each patient to ensure the highest probability

of a successful outcome. It was then that the importance of the math behind proper dosing began to truly crystallize in my mind.”

Dr. Lodise notes one individual who was a mentor to him. Peggy McKinnon, Pharm.D., a clinical specialist at Detroit Receiving Hospital and fellowship director, confirmed and further stimulated an already growing interest for Dr. Lodise—how to optimize patient care and ef-ficiently pit antibiotics against infection. This was enough to jumpstart a successful career as a clinical scientist, although it also didn’t hurt that his first paper was accepted and published in the flagship journal, Clinical Infectious Diseases. To date, Dr. Lodise has published approximately

The Mind of the Researcher

Faculty Research

27

50 peer-reviewed articles in Clinical Infectious Diseases and other such reputable journals, including Antimicrobial Agents and Chemother-apy, Chest; Pharmacotherapy; and the Journal of Antimicrobial Chemotherapy.

Not surprisingly, in 2006, Dr. Lodise was named Researcher of the Year by the New York State Chapter of The American College of Clini-cal Pharmacy (NYS-ACCP). In 2008, he was named the Young Investigator of the Year by the Society of Infectious Diseases Pharmacists (SIDP), who also awarded Dr. Lodise with the Infectious Diseases Pharmacotherapy Paper of the Year Award in 2010.

Good science certainly requires good collabo-ration. As such, Dr. Lodise is not alone in his endeavors. The study of infectious diseases is a budding area at the College. In addition to Dr. Lodise, there are currently four other faculty members with advanced training and expertise in infectious diseases pharmacotherapy, clinical pharmacokinetics, epidemiology, outcomes research, and mathematical modeling. These faculty members are Christopher Miller, Pharm.D., Tony Nicasio, Pharm.D., Amit Pai, Pharm.D., and Nimish Patel, Pharm.D. Integrating their dual interests in research and patient care, their overall research goals are to advance the science of infectious diseases and improve clinical practice.

Dr. Lodise also works closely with Leon Cosler ‘82, Ph.D., director of the Research Institute for Health Outcomes (RIHO), an institute formed at the College in 2006 in response to demand for high-quality, scientifically sound medical and financial data in health outcomes and phar-macoeconomic research.

A year earlier, in 2005, the Albany Nephrology Pharmacy Group (ANephRx) was formed to investigate medication-related issues in kidney disease, quickly becoming another collaborative entity at the College. Dr. Lodise works closely with ANephRx founding member Darren Grabe ‘95, Pharm.D., and Katie Car-done ‘06, Pharm.D., both of the Department of Pharmacy Practice.

Beyond the College, Dr. Lodise works with a wide variety of collaborators, including col-leagues at Albany Medical Center Hospital (Albany, NY), Ordway Research Institute Inc. (Albany, NY), State University of New York School of Public Health (Albany, NY), Universi-ty of Buffalo School of Pharmacy (Buffalo, NY), Strong Memorial Hospital (Rochester, NY), Albany Stratton VA Medical Center (Albany, NY), the Hortense and Louis Rubin Dialysis Center (Clifton Park, NY), Northwestern Medi-cal Center University (Chicago, IL), and Wayne State University (Detroit, MI).

Given his enemy is MRSA, how does Dr. Lodise stay ahead of the curve in developing sound and effective antibiotic regimens? How does his mind work? What can we learn from such an effective clinical scientist?

Hypotheses from the bedsideA 1999 summa cum laude doctor of pharmacy graduate of Temple University School of Phar-macy in Philadelphia, Dr. Lodise completed the APhA-ASHP-accredited Pharmacy Practice Residency at Thomas Jefferson University Hospital, also in Philadelphia, in 2000. In 2002, after completing the Infectious Diseases Pharmacotherapy and Outcomes Fellowship at Wayne State University in Detroit, he joined the faculty at Albany College of Pharmacy and Health Sciences.

Eight years later, he finds a comforting mix of the clinical life, the life of a researcher, and the rewards of being a teacher. “These three aspects of life here complement each other daily,” says Dr. Lodise. “And the College recognizes the importance of intertwining the three. I have the academic freedom to best figure out how to conduct my research and deliver a quality educational experience to each student that crosses my path.”

Although at first Dr. Lodise planned to embark on a purely clinical career, his research interests brought him to the College where his focus today is clear.

“The most problematic organism posing major health risks today is MRSA,” says Dr. Lodise. Death rates of those infected in the United States are estimated to be a staggering 20-30%. Those who do survive then tend to be more susceptible to recurrent infections that are often less responsive to antibiotics. It’s often an uphill battle. Key to Dr. Lodise’s research is finding that “sweet spot” where the optimal dosing of antibiotics is administered to a patient, thus providing the most bacterial-fighting capac-ity while causing the least amount of toxicity risk and, equally important, future antibiotic resistance. By no means an easy task. And the results directly affect human lives.

Harkening back to his fellowship days, Dr. Lodise always begins his research at the bed-side. “Hypotheses are generated at the bedside,” he says, “through your interactions with the patient, the observations you make, the patterns that begin to emerge.” Each patient contributes new and invaluable data that together forms those patterns that, in Dr. Lodise’s terms, move the science forward.

28

While this process may start with the question of how to properly dose a specific antibiotic or which antibiotic to administer, other questions undoubtedly present themselves. Why is this patient’s infection not responding to the stan-dard treatment? What’s driving the resistance mechanism of this infection?

In Dr. Lodise’s own words, “Since we often find the standard approach to care is not the optimal way of maximizing patient outcomes, can we identify some other pattern here, even if it challenges currently accepted paradigms?” Once these new patterns emerge, ideas and hypotheses can take shape and be modeled for evaluation. “Part of this process is seeing where these ideas can fill those gaps in the literature,” says Dr. Lodise, emphasizing the crucial need for staying current with relevant research in the field.

And while having a firm understanding of the science behind your observations is key, Dr. Lodise notes the importance of taking this to the next level by discussing a hypothesis with experts in other disciplines “to be as fully informed as possible.”

Dr. Lodise enjoys working with people he can learn from, which perhaps explains his uncanny knack for avoiding the so-called “silo effect” in which scientists in any discipline unknowingly isolate themselves from the other sciences and knowledge in the surrounding academic and clinical worlds. Answers, or at least clues, often lie in the unexplored synergies of the sciences.

“I want to know how these bacteria behave,” says Dr. Lodise, “so I turn to a microbiologist to find those links, those connections to my field, to better understand what I’m up against.” Combining such alternative viewpoints and perspectives from a variety of fields leads Dr. Lodise to stronger hypotheses, as well as crucial partnerships and collaborations. This multidisciplinary strategy and crosspollination does indeed take time, though in our modern age, such a collaborative approach has certainly become easier, enabling Dr. Lodise and others to communicate with fellow scientists across the globe.

“The goal is to improve patient care, plain and simple,” says Dr. Lodise. “So when we find that pattern or develop a hypothesis that challenges the norm, I’m excited. Let’s move the science forward and change the currently accepted paradigm.” Dr. Lodise is always on the lookout for ways to innovate and also translate new findings in science into tried and true practice back at the bedside.

From the bedside to the classroom to the benchIn his current role at the College, Dr. Lodise teaches core courses in infectious diseases phar-macotherapy and drug information (focusing on statistics and the design and implementation of effective clinical studies), as well as an elec-tive course in epidemiology. Since joining the College in 2002, Dr. Lodise has actively served as preceptor for both clinical and research rota-tions in infectious diseases. He is also the Infec-tious Diseases Fellowship Director at the Col-lege. With other similar accolades over his eight years at the College, Dr. Lodise understands the importance of teaching and mentoring, includ-ing its positive impact on his research.

“There’s a very human cycle here that’s worth maintaining and developing further,” says Dr. Lodise. He’s referring to the experiential cycle in which students and post-docs ultimately becomes mentors, a cycle in which Dr. Lodise continues to play an increasingly crucial role at the College.

“This is what distinguishes academia from the purely clinical environment,” he says. Students learn and through their work both as a student and in their postgraduate careers, help move the science forward. Not only do his students learn and experience their craft firsthand through his efforts, Dr. Lodise also stumbles upon new find-ings and new experiences along the way, a role he finds very rewarding.

“Students and post-docs are accountable for improved patient results,” says Dr. Lodise, “and therefore experience being vital members of the team.” He also stresses the importance of get-ting students involved as early as possible.

His passion is evident when describing to his students the significance of mathematical modeling and statistics in the design of clinical studies. “Be as specific as possible and let the data tell us something,” says Dr. Lodise. “Num-bers don’t lie, even when they don’t support our hypothesis.” The importance of designing and administering a study cannot be underes-timated, as this serves as the means to moving the science forward, though not necessarily in the anticipated direction.

“A hypothesis can only exist if it cannot be dis-proven,” says Dr. Lodise. As a clinical scientist, he views one of his key job requirements as being a good dose of skepticism.

And as impersonal as it may sound, Dr. Lodise also believes that the mechanics of research—

“ The goal is to improve patient care, plain and simple.”

29

the details of its execution—must be treated as a business for the research to be successful. “We can always learn from previous studies ways to design and implement more efficiently executed studies in the future,” says Dr. Lodise. Why slow yourself down by getting caught up with the inherent inefficiencies of the process? Find ways to improve.

In addition to improving efficiency, Dr. Lodise looks for ways to improve the thoroughness of his studies. “Research should be done for the sake of finding things out,” he says, “and ulti-mately patient care.” So while a study certainly has definitive goals, most of which are met and discussed along the way, Dr. Lodise remains vigilant in his search for new and surprising bits of information—the hidden clues as to where to direct his efforts next.

Maintaining the momentumWhile his focus and driving force is clearly to improve patient care, Dr. Lodise also finds mo-tivation in challenging himself and growing as an individual. “Science is indeed a science, but it is also an art,” he says. Like artists in almost any field, Dr. Lodise has an idea, he develops it, and then he expresses it. “In my mind,” he says, “those artifacts of research—data, results, seminars, presentations, papers—are all a form of self-expression, though by their very nature they are more technical than the other arts.”

Perhaps another key to Dr. Lodise’s success is his focus on the all-important discussion sections of his papers. “The discussion section is where ideas and hypotheses thrive,” he says. “Though I disliked writing even back in my undergraduate studies at Temple University, I can say now that I look forward to writing those

discussion sections, as hard as they are to write.”

And like many embarking on such intensive efforts, starting is often the hardest part for Dr. Lodise. Opposite the starting gate is the finish line, and though there are many finish lines ac-cording to Dr. Lodise, each is crucial to moving the science forward. As Dr. Lodise continues to excel in his field, he certainly carves out time to reflect on his expanding career, identify-ing those work habits of his own that he can improve. “My advice to younger researchers is to follow your ideas and hypotheses through to completion. Keep the momentum going. I’ve seen researchers give up the fight too early or become stagnant in their approach to research. They lose their passion for the science.”

Dr. Lodise remains passionate about his re-search, often returning to his “move the science forward” mantra. And while seeing the fruits of one’s labors is certainly a fulfilling feeling for Dr. Lodise—for example learning of yet another pa-per’s acceptance in a reputable and widely read journal—he notes the process of getting there to be of equal significance. “Earning the ‘win’ is of course beyond measure,” he says. “But the rewards of good science and well-executed me-

chanics are also very gratifying, not to mention the collaborations with colleagues and others passionate about their work.”

The end game without endWhen does research reach its end? Or does it?

“Research requires constant refinement,” says Dr. Lodise. Unlike football, there is no two minute warning, no imminent end of the game. Deadlines come and go. Papers and results are produced and published, progress is made, and the journey continues.

“My hope, always, is to identify how to move the science forward,” says Dr. Lodise. “How can we broaden and upscale our ideas, establish reusable patterns, for example, and apply them to the treatment of other bacterial infections, or even other seemingly unrelated problems?”

Dr. Lodise’s quest for knowledge and under-standing has also led him to working on his Ph.D. in epidemiology from the State University of New York School of Public Health, no small feat for one so busy with clinical work, teaching, and research. “Earning my Ph.D. will certainly be a culmination of much of my work to this point,” says Dr. Lodise. He also credits the Col-lege for providing such a unique and synergistic opportunity.

And as for his Philadelphia Eagles, rest assured that Dr. Lodise still finds comfort in watching his team in midnight green.

“My advice to younger researchers is to follow your ideas and hypotheses through to completion. Keep the momentum going.”

30

The Student and the WorldIn support of ACPHS’s strategic plan and institu-tional goals, the College has made great strides in recruiting international students and providing them with world-class resources.

For the 2009-2010 year, the College was ranked among the top 30 for international students among specialized colleges, according to the As-sociation of International Educators. The College has 140 international students, comprising nearly ten percent of its total enrollment. Recent college initiatives, including the founding of the Office of Intercultural Affairs and Diversity, the hiring of an English-as-a-Second-Language teacher, international recruitment trips, and the ongoing search for a Vice President of Campus Life, speak to ACPHS’s interest in diversifying and providing for its international student body.

Many current international students reveal that the quality of ACPHS’s academics and support systems outside of the classroom have far ex-ceeded their expectations. International students currently enrolled at the College have found their experiences differ widely from previous studies.“It’s tough for people from professional backgrounds to make the transition to a less structured environment,” said Hassan El-Fawal, Ph.D., Chair of the Department of Health Sci-ences. Dr. El-Fawal works closely with the 20 medical students from Saudi Arabia’s King Saud University (KSU) who are currently enrolled in the master’s program in Biotechnology. “A cooperative environment has developed, as the

students realize they are no longer in competition with each other,” he added.

After receiving their master’s degrees from ACPHS, the KSU students plan to complete international medical residencies or pursue Ph.D. programs before returning to KSU, the oldest university in Saudi Arabia, for faculty positions. Despite only having one semester of study and many different career goals, several Biotechnol-ogy students already attest that the program has impacted their thinking and lab skills and will influence their careers into the future.

“It changed the way I think in that I wouldn’t think of a disease by itself, I would think of treatments used in disease,” Lana Shaiba, a KSU student who plans to become a pediatrician, said. “[It has taught me] how to use basic science instead of a clinical approach. It made me realize how important that is in medicine.”

Jalal Jalaly, another Biotechnology student from KSU, said the options and independence students are given is new and appealing to him. He said Vice Provost for Research and PRI Chairman Shaker Mousa gave students the option of an exam or literature review. Jalaly chose the review, which was novel and exciting to him, and tapped into an entirely different set of skills. “This offer was an opportunity to build you and build your research skills,” he said. “Courses are student driven. You have to choose what you want and commit to it.”

Rachel Schiewe, a Canadian MS Biotechnology student who attended the University of Alberta, said she wants to be a lab manager and will benefit from the practical skills the Biotechnology program will impart.

“We are more engaged in subjects,” she said. “We try to think about how we’re going to use the material.”

El-Fawal said he wants students to think cre-atively and independently and be productive. To inspire motivation, he asks students what they want their recommendation letter to say. “The grades you receive as an undergraduate will not matter as much as how you think. That’s what people want to know when they look at your C.V.,” he says.

Outside of the Biotechnology program, several international students agree their ACPHS experi-ences have been positive and practical. Zhanbin Wang, who came from China and is a student in the Pharmaceutical Science master’s program, said ACPHS faculty members have provided him with the resources to become an accomplished scientist.“ACPHS grants us the opportunity to reach an upper level of understanding through self-study by offering us electronic resources as well as experienced faculty to aid us on our path to forming our careers,” Wang said.

Aditi Baxi, a Pharm.D. student from Canada, also recognizes the vast resources the College has. “Along with studying the theories, the faculty

Student Research

31

believes in training students to work and excel in the work environment and therefore we receive an ultimate mixture of both,” Baxi said. “The Dean and the entire faculty are very easily acces-sible and helpful. Also, the students are a great support since no one really competes against each other, rather they help and motivate others to excel and this is the true quality of

a health professional. “

Albany Pharmaceutical Sciences Chair and Di-rector of Graduate Studies Bill Millington said he believes there is truly an international exchange by having international students on ACPHS’s campuses. Cultural competency and faculty pro-ductivity, which can lead to grant money, advance

the College and its place in the world. “We want to infect the entire globe with our graduates. A lot of them will go back, and we will have contacts throughout the world. Hopefully, that will ad-vance the science and health in other places.”

32

33

34

Student Research

Jessica Phelps ’11Student in the Bachelor’s Program in Pharmaceutical Sciences

Jessica Phelps has worked with Dr. Luciana Lopes in the development of subcutaneous liquid crystalline gels for treatment of drug addiction. The gels are intended to sustain the delivery of naltrexone, decreasing the frequen-cy of dosing and increasing patient compliance during treatment. Because the liquid crystal-line gel is too viscous to inject, they started developing fluid pre-concentrates that can be injected subcutaneously and spontaneously form the gel in situ upon absorption of water. Thus far, BRIJ- and Phytantriol- based fluid and injectable formulations have been devel-oped. Both formulations can form hexagonal phase gels within a few hours upon absorption of water, which can sustain naltrexone release for several days. Further investigation is neces-sary to evaluate the safety of such formulations in vivo, and whether enough drug is absorbed to elicit the desired effect.

35

Michael D’Alessandro ‘13Student in the Bachelor’s Program

in Pharmaceutical Sciences

Mike D’Alessandro is working with Dr. Susan Ludeman, synthesizing deuterium labeled compounds related to cyclophosphamide (CP). Cyclophosphamide is the most widely used anticancer drug and has been for nearly half a century; it is effective against more than half of all cancers. Most, if not all, drugs have adverse effects and those associated with CP include neurotoxicity and therapy induced leukemia. These may be linked to an unde-sirable metabolism of CP by certain liver enzymes. By replacing hydrogen with its less reactive isotope, deuterium, at the site of un-desirable metabolism, it is hypothesized that “metabolic switching” will occur. That is, the metabolic pathway which produces toxic metabolites will be suppressed while a competing metabolic pathway which gives therapeutic metabolites will be enhanced. Using human liver microsomes, labeled and unlabeled drugs are allowed to metabolize and then the relative ratios of toxic and therapeutic metabolites are measured. If their hypothesis of ‘metabolic switching’ is correct, the deuterium labeled drug should generate a lower concentration of toxic metabolites and, therefore, should increase the therapeutic benefits of cyclophosphamide for those undergoing chemotherapy. This work is being done in collaboration with researchers at the Comprehensive Cancer Centers of the University of Chicago and Duke University.

36

Zhanbin Wang ‘12Student in the Master’s Program in Pharmaceutical Sciences

Passage of drug molecules through a phos-pholipid bilayer takes between milliseconds to days, depending on the drug structure. Molecules with intermediate strength of the interactions with individual bilayer regions pass the bilayer quickly. Extremely weak or strong interactions lead to a slow trans-port. Zhanbin Wang worked with Dr. Rajesh Subramaniam, a postdoctoral associate in Dr. Stefan Balaz’s lab, on the partitioning experi-ments that aim at the characterization of the drug-region interactions. To obtain solvation characteristics of drug candidate molecules in the microscopic regions of phospholipid bilayers, surrogate phases imitating the regions are used. The headgroup surrogate is repre-

sented by a concentrated solution of diacetyl phosphatidylcholine that contains about the same amount of water as in the bilayer under physiological conditions. Hexadecane serves as the core surrogate. Zhanbin used UV/VIS/NIR spectrometry to characterize partitioning of several drug candidate molecules. He will continue his work as a part of his research- oriented MS in Pharmaceutical Sciences degree. Understanding the influence of drug structure on the trans-bilayer transport rate is crucial for designing drugs with tailored distribution in the body. Limited distribu-tion is needed for drugs acting locally, while general distribution is preferred for drugs targeting receptors in the entire body.

37

Student Research

Michael Camuso ‘12Student in the Doctor of Pharmacy Program

Michael Camuso’s ‘12 family has worked in community pharmacy for almost 30 years, but this Pharm.D. student’s interests are centered on pharmaceutical research, discovery, and clinical applications.

Camuso has assisted in the lab of Pharma-ceutical Sciences Associate Professor Rich-ard Dearborn, Ph.D., for the past two years, investigating Vitamin D3 up-regulated protein (VDUP1). VDUP1 is a regulatory protein found in the cells of organisms as diverse as fruit flies and humans. Since being identified as a protein that is shut down in cancer cells, VDUP1 has become a target for study in labo-ratories worldwide.

Using the powerful genetic tools associated with the fruit fly model, Dr. Dearborn’s lab

has shown that VDUP1 is also essential to nervous system development, in addition to its role in cancer. With this knowledge, a new clue has emerged in determining what controls when VDUP1 is turned on or off – a regulatory pathway called the Hedgehog (Hh) signaling pathway.

The Hh pathway is overactive in several cancer types, though it is not known why it causes ab-normal cell division. Michael has worked with Dr. Dearborn on establishing a link between Hh signaling and VDUP1 expression. This research has taken many forms – for example, Michael has dissected and tested flies to see how changes in Hh signaling affect VDUP1 expression and what consequences these ma-nipulations have on brain development.

In collaboration with Pharmaceutical Science Associate Professor Jeffrey Voigt, Ph.D., Mi-chael and Dr. Dearborn have further examined the regulation of VDUP1 in human breast cancer cells. Through genetic and biochemical experiments, they have established that Hh signaling is a primary regulator of VDUP1 in human cells as well.

If the researchers can generate a fly-based VDUP1 tumor model to complement the human tumor cell system, they may be able to find additional ways to control VDUP1, and in the process, help slow or even stop the growth of cancer cells.

38

Student Research

Linh Nguyen ’12Student in the Doctor of

Pharmacy Program

When Assistant Professor of Pharmaceutical Sciences HaiAn Zheng, Ph.D., was a pharmacy student, he used diagrams and images to help learn his coursework. As a graduate student, computer modeling played an important part in his research initiatives. Now that he is a fac-ulty member, Dr. Zheng continues to explore different multimedia tools to help students learn complex pharmacy-related topics, and fifth year pharmacy student Linh Nguyen plays a key role in these efforts.

For the last three years, Linh has worked with Dr. Zheng to integrate visual aids into his classes through the “Pharmaceutics in Mo-

tion” project. At first, Linh created animations for molecular structures and processes like osmosis, supplementing traditional text-based materials. Based on positive feedback from students, Dr. Zheng and Linh created and sought out additional multimedia elements such as molecular modeling, video, and com-puter simulations to be used for the class.

Survey results of students have confirmed that Linh and Zheng’s multi-media presenta-tions have greatly helped in understanding the physical, chemical, and biological principles of drug delivery and product preparation. In fact, the results have been so encouraging, that Dr. Zheng and Linh (along with Xun Gong,

Luciana Lopes, and Judy Teng) were invited to present their results at the annual meeting of the American Association of Colleges of Pharmacy (AACP) in 2010.

As the world continues to advance into the digital realm and web sites like YouTube increase in popularity, students are becoming increasingly accustomed to acquiring infor-mation through visual and auditory stimuli. The work being done by Dr. Zheng and Linh through Pharmaceutics in Motion may point the way to a new way of teaching and learning pharmaceutics in the 21st century.

39

40

Financial Report July 1, 2009 to June 30, 2010

ASSETSCash and cash equivalents $ 26,781,876 Investments 10,186,258Other assets 2,378,802Accounts receivable - Students 268,830Receivables - Government entities 1,726754Pledges receivable 1,644,487Student loan receivable 2,234,689Other receivables 627,214Agency funds 241,846Deposits with Bond Trustees 1,755,041Property, plant & equipment - Net 52, 296, 305

Total Assets $ 100,142,102

Net AssetsUnrestricted net assets $ 45,613,790 Temporarily restricted assets 2,182,438Permanently restricted assets 5,675,400

Total Net Assets $ 53,471,628

Total Liabilities and Net Assets $100,142,102

40

LIABILITIES AND NET ASSETS Liabilities Accounts payable and accrued liabilities $ 5,112,787 Deferred income and deposits 7,875,100U.S. government grants refundable 2,205,911Bonds payable 29,094,745Expected post retirement benefit obligation 1,207,642Other liabilities 932,443Deposits held in custody for others 241,846

Total Liabilities $ 46,670,474

Balance Sheet

41

REVENUES % OF TOTALStudent tuition and fees 73.21% Auxilliary enterprises 8.02%Gifts and pledges 6.70%Government contracts and grants 6.67%Other sources 3.65%Investment income 1.39%Postgraduate education 0.36%

Total 100.00%

EXPENSES % OF TOTALInstruction/Student services 39.68%Physical plant 26.26%General administration 19.74% Research 9.33%Institutional advancement 2.75%Student financial aid 1.87%Postgraduate education 0.37%

Total 100.00%

41

Statement of Activities

42

Dept. of Pharmacy Practice PUBLICATIONSJeanine Abrons/Jennifer Cerulli/Shannon Miller/Tanya VadalaAbronsJ,VadalaT,MillerS,CerulliJ.EncouragingSafeMedicationDisposalThroughStudentPharmacistIntervention.J Am Pharm Assoc 2010;50(2);169-173.

Magdalene Assimon/Amy Barton Pai AssimonM,Mousa SA,ShakerO,PaiAB.TheEffectofSevelamerHydrochlorideandCalciumBasedPhosphateBindersonMortalityinHemodialysisPatients:ANeedforMoreResearch.Consultant Pharm. 2010;35:37-51

George Bailie BailieGR,MasonNA,ValaorasTG.Safetyandtolerabilityofintravenousferriccarboxymaltoseinpatientswithirondeficiencyanemia.Hemodial Int 2010;14:47-54.

Jennifer Cerulli CerulliC,CerulliJ,SantosEJ,LuN,HeH,KaukeinenK,WhiteAM,TuX.DoesHealthStatusofIntimatePartnerViolenceVictimsWarrantPharmaciesasPortalsforPublicHealthPromotion? J Am Pharm Assoc 2010;50(2);200-206.

Brian Cowles LeeBR,LubschL,CowlesB,GatlinL.Positionstate-mentonantidepressantuseinchildren.PreparedforthePediatricPharmacyAdvocacyGroup.July23,2009.Accessedfrom:http://www.ppag.org/SSRI/

Jessica Farrell FarrellJ,GumanovD.Propoxyphene:AnAntiquatedAnalgesic.CORRONA News,3(2),7-8.2009Aug5.[Epubaheadofprint]

FarrellJ.PatientAssistanceProgramsforBiologics.CORRONA News,3(2),9.2009Aug5.[Epubaheadofprint]

FarrellJ,SiddonA.SodiumOxybate(Xyrem)forFibro-myalgia.CORRONA News,3(2),10.2009Aug5.[Epubaheadofprint]

FarrellJ,SiddonA.VitaminDCanHelpYourHeart,Too?CORRONA News,3(2),11-12.2009Aug5.[Epubaheadofprint]

FarrellJ.FDAUpdates:Rheumatology.CORRONA News,3(2),12-14.2009Aug5.[Epubaheadofprint]

FarrellJ,GiordanoS.LeflunomideInducedPeripheralNeuropathy:IsYourPatientatRisk?CORRONA News, 3(3),5-6.2009Oct9.[Epubaheadofprint]

FarrellJ,DispirtoA.Nucynta(tapentadol):ANewMedicationforPainManagement.CORRONA News,3(3),6-7.2009Oct9.[Epubaheadofprint]

FarrellJ,BradleyC.AssessmentofLongTermUseofOralBisphosphonates.CORRONA News, 3(3),7-10.2009Oct9.[Epubaheadofprint]

FarrellJ.FDAUpdates:Rheumatology.CORRONNA News,3(3),11-14.2009Oct9.[Epubaheadofprint]

FarrellJ,HughesD.“Reactivating”theDiscussionofAnti-TNF- AgentUseinChronicHepatitisCVirus.CORRONA News,4(1),8-9.2010Jan.

FarrellJ,DilibertoD.ProtonPumpInhibitorsandClopidogrel:ShouldYouChangetheTreatmentRegimen? CORRONA News,4(1),10-11.2010Jan.

FarrellJ,BradleyD.Interleukin-1InhibitorShowsPromiseforGoutPatients.CORRONA News,4(1),11-13.2010Jan.

FarrellJ.FDAUpdates:Rheumatology.CORRONA News,4(1),13-15.2010Jan.

FarrellJ.CurrentApproachestoDiseaseModifyingAnti-RheumaticDrug(DMARD)Therapy.ACPHS.March20,2010.

Gina Garrison GarrisonGD,LubowskiTJ,Miller SM,Strang AF,SorumPC,Hamilton RA.AMulti-sitePharmacyStudentCoronaryHeartDiseaseRiskAssessmentServiceintheAmbulatoryCareSetting:ExperientialEducationandPatientSatisfaction.American Journal of Pharmacy Education(inpress).

GarrisonGD,LubowskiTJ,Miller SM,Strang AF,SorumPC,Hamilton RA.Multi-siteHeartDiseaseRiskAssessmentServiceProvidedbyPharmacyStudent,American Journal of Pharmaceutical Education2010;74(3).

Thomas Lodise/Nimish Patel LodiseTP,PatelN,LomaestroBM,RodvoldKA,DrusanoGL.RelationshipbetweenInitialVancomy-cinConcentrationTimeProfileandNephrotoxicityamongHospitalizedPatients.Clin Infect Dis. 2009Aug15;49(4):50714.

PatelGP,SimonD,ScheetzM,CrankCW,LodiseT,PatelN.TheEffectofTimetoAntifungalTherapyonMortalityinCandidemiaAssociatedSepticShock.Am J Ther.2009Jun13.[Epubaheadofprint]

PatelGW,PatelN,LatA,TrombleyKC,EnbaweS,SmithR,LodiseTP.OutcomesofExtendedInfusionPiperacillin/TazobactamforDocumentedGramnegativeInfections.Diag Microbio Infect Dis.64(2009)236–240.

Christopher Miller/Nimish Patel AdamsJ,PatelN,MankaryousN,TadrosM,MillerCD.Non-NucleosideReverseTranscriptaseInhibitor(NNRTI)ResistanceandtheRoleofSecondGenera-tionAgents.Ann Pharmacoth2010;44157-165.

Sean Mirk MirkSM,BurkiewiczJS,KompeK.StudentPerceptionofaWikiinaPharmacyElectiveCourse.Currents in Pharmacy Teaching and Learning.Volume2,Issue2,Pages72-78(March2010)

Sarah Scarpace BurkiewiczJS,ScarpaceSL,BruceSP.Denosumabinosteoporosisandoncology.Ann Pharmacother2009;43:1445-1455.e-publishedaheadofprinton21Jul2009atwww.theannals.com,DOI10.1345/aph.1M102

Joanna Schwartz Schwartz,J.Currentcombinationchemotherapyregimensformetastaticbreastcancer.Am J Health Syst Pharm Dec2009;66:3-8.

Information collected from July 1, 2009 to June 30, 2010.

Scholarly Activity Report

43

PreviouslyPublishedArticlesSelectedforInclusionintheAnnalsofPharmacotherapyEvolutionofClinicalPharmacy40YearsofProgress;2009.

Margaret Malone MaloneM.Theobesitypandemic-howdidwegethere?EoC2009;298-9.

Jennifer Cerulli/Margaret Malone CerulliJ,LomaestroBM,MaloneM.UpdateonthePharmacotherapyofObesity.EoC2009;300-312.

INVITED PRESENTATIONSGeorge Bailie BailieGR.“Regulatorypathwayforironsucrosesimilars”,ComplexBiologicalsSymposium,Leiden,Holland.October2009.

Michael Brodeur BrodeurMR,JoffeeL.NDMS“PharmacyOperationsandPointsofDispensing.”NationalDisasterMedicalSystem,DepartmentofHealthandHumanServices.WestchesterMedicalCenter.June28,2009.

BrodeurMR.“EvaluationofPharmacotherapyofOlderAdults:ABeersCriteriaReview.”OfficeofPostgradu-ateEducation.AlbanyCollegeofPharmacyandHealthSciences.September2009.

Katie Cardone CardoneKE.“Pharmacologicaspectsofcomplicatedhypertension.”AmericanNephrologyNurses’Associa-tionFallMeeting,Orlando,FL,Oct2009.

CardoneKE.“Preventingend-stagekidneydisease:Interventionsinthecommunitypharmacy.”11thAnnualSouthwestNephrologyConference,Phoenix,AZ,Feb2010.

CardoneKE.“Medicationmanagementinchronickidneydisease:Focusoncomplicationsandspecialconsiderations.”11thAnnualSouthwestNephrologyConference,Phoenix,AZ,Feb2010.

Jennifer Cerulli CerulliJ.“MedicationTherapyManagement:WhatisitandwheredoIstart?”(3hoursACPE#0170-9999-10-0140L01-P).CapitalAreaPharmacistsSociety,Albany.March7,2010.

Brian Cowles CowlesB.“AcuteOtitisMedia:Guidelines,Vaccines,andYou.”ACPHS2010PharmacyPracticeSymposium;AlbanyNY/ColchesterVT(ACPECE).March20,2010.

CowlesB.“Child&AdolescentBehavioralMedicine&MedicationTherapy.”NortheastParent&ChildSociety/UniversityatAlbanySchoolofSocialWelfare;SchenectadyNY(Invitedpresentation).March26,2010

CowlesB.“AntibioticProphylaxisforRecurrentUTIinInfants&Children.”VtSHPAnnualMeeting,Burlington,VT(ACPECE).April10,2010.

CowlesB.“MedicationUseandChildreninFosterCare.”21stAnnualFosterCare&AdoptionConfer-ence,NYSCitizen’sCoalitionforChildren;Albany,NY(Invitedpresentation).May7,2010.

CowlesB.“NeonatalAbstinenceSyndrome.”Roundslecture,FletcherAllenDepartmentofPharmacyOctober1,2009.

Ronald J. DeBellis DeBellisRJ.“ClinicalConsiderationsinCOPD.”NYS-SHPContinuingEducationProgram,Latham,NY,November2009.

Jessica Farrell FarrellJ.“MedicationRelatedIssuesinScleroderma.”CapitalDistrictSclerodermaFoundationSupportGroup,Schenectady,NY.November11,2009.

Gina Garrison GarrisonGD.“TobaccoCessation”(1hourACPEContinuingEducation).ACPHSPharmacyPracticeInstitute,Albany,NY.March24,2010.

Garrison,GD,LytleJ.“LegislativeUpdate:WhatEveryPharmacistNeedstoKnowaboutRecentDevelop-mentsinNewYorkStateLawandRegulation.”NewYorkStateCouncilofHealth-SystemPharmacistsAn-nualAssembly(1hourCE),Saratoga,NY.May2010.

Nimish Patel/Katie Pallotta-Cardone/Darren Grabe/Thomas Lodise/PatelN,PallottaK,GrabeDW,MeolaS,HoyC,Dru-sanoGL,LodiseTP.“Daptomycin(D)Pharmacokinet-ics(PK)inPatients(Pts)ReceivingStandardized3XWeeklyHemodialysis(HD).”Abstract#2514.PosterPresentationatthe49thInterscienceConferenceonAntimicrobialAgentsandChemotherapy(ICAAC).SanFrancisco,CA.September2009.Presenter:Patel

PatelN,PallottaK,GrabeDW,MeolaS,HoyC,Dru-sanoGL,LodiseTP.“Daptomycin(D)Concentration(Conc)TimeProfileinHemodialysis(HD)Patients(Pts).”Abstract#1242.PlatformPresentationatthe47thAnnualMeetingoftheInfectiousDiseasesSocietyofAmerica,Philadelphia,PA.October2009.Presenter:Patel

Nicole Lodise LodiseNM.“HypoactiveSexualDesireDisorder:AnOverviewandApproachtoPatients.”AmericanPhar-macistsAssociationAnnualMeeting.WashingtonDC,March15,2010.

Thomas Lodise/Nimish Patel/Amit Pai PatelN,Grifasi,M,PaiM,RodvoldK,DrusanoGL,Lo-diseTP.“Vancomycin(V):WeCanNotGetThereFromHere.”Abstract#193.PosterPresentationatthe47thAnnualMeetingoftheInfectiousDiseasesSocietyofAmerica,Philadelphia,PA.October2009.Presenter:Lodise

Thomas Lodise/Nimish Patel VanDeWalH,PatelN,TristaniL,GrifasiM,DihmessA,SmithR,LodiseTP.“IncidenceofThrombocytopenia(TCP)AmongVeterans’Affairs(A)Patients(Pts)thatReceivedLinezolid(L).”Abstract#200.PosterPresenta-tionatthe47thAnnualMeetingoftheInfectiousDis-easesSocietyofAmerica,Philadelphia,PA.October2009.Presenter:VanDeWal

Bolded nameswithincitationsindicateACPHSfacultycollaborators.

44

LodiseT,PatelN,HedgeS,ShawJ,BarriereS.Drusano,GL.“MousethighMRSAinfectionmodeldataandmathematicalmodelingtodeterminetelavancindosingforcomplicatedskinandskinstructureinfec-tiontrials.”Abstract#469.PosterPresentationatthe20thEuropeanCongressofClinicalMicrobiologyandInfectiousDiseases.Vienna,Austria.April2010.Presenter:Lodise

LodiseT,PatelN,HedgeS,ShawJ,BarriereS.“Tela-vancinpharmacokineticsandpharmacodynamicsinpatientswithcomplicatedskinandskinstructureinfectionswithvaryingdegreesofrenalfunction.”Ab-stract#468.OralPresentationatthe20thEuropeanCongressofClinicalMicrobiologyandInfectiousDiseases.Vienna,Austria.April2010.Presenter:Lodise

TristaniL,PatelN,WooB,DihmessA,VanDeWallH,LiH,SmithR,LodiseT.“LackofserotoninsyndromeamongVeteranAffairspatientsreceivinglinezolid.”Abstract#464.PosterPresentationatthe20thEuropeanCongressofClinicalMicrobiologyandInfectiousDiseases.Vienna,Austria.April2010.Presenter:Patel

Christopher Miller

MillerC.“AnUpdateonInfluenza.”ACPHSRespiratoryTherapyUpdate.Albany,NY.January14,2010.

MillerC.“AnUpdateonAntiretroviralTherapy.”InfectiousDiseasesAnnualUpdate.ACPHS.February7,2010.

MillerC.“CurrentStrategiesintheTreatmentofHIVInfection.”Pharm.Ed.Conference.DesmondHotel,Albany,NY.February24,2010.

MillerC.“AntiretroviralApproachtotheNewHIVPatient.”MedicalGrandRounds–EllisHospital.Schenectady,NY.March23,2010.

Anthony Nicasio NicasioAM.“Community&HospitalAcquiredPneumonia:ATherapeuticOverview.”ACPHS.February7,2010.

Sarah Scarpace Scarpace,SL.“GIToxicities.”PresentedaspartoftheOncologyBootcamppre-meetingsymposiumatthe6thannualHematology/OncologyPharmacists’Association(HOPA)Meeting,NewOrleans,LA.March24,2010.

Scarpace,SL.“Cancer-andChemotherapy-inducedBoneLoss.”30minute-ACPE-accreditedinvitedpresentationattheAmericanAcademyofManagedCarePharmacistsannualmeeting,April8,2010.SanDiego,CA.

Scarpace,SL.“OncologicEmergencies.”1-hourACPE-accreditedinvitedpresentationattheNewYorkStateCouncilofHealth-systemsPharmacistsAnnualAssembly.May7,2010.SaratogaSprings,NY.

Scarpace,SL.“TyrosineKinaseInhibitors:FocusonAdherence.”ACPE-accredited1-hourprogrampresentedtohematology/oncologypharmacists,pharmacytechnicians,andnursesatthe2009North-easternHematology/OncologyPharmacists’Society(NEHOPS)AnnualMeeting,Danvers,MA,October2–3,2009.RepeatedattheAnnualBarbaraDiLasciaOncologyUpdateatAlbanyCollegeofPharmacyandHealthSciences,Albany,NY,October18,2009.

Joanna Schwartz “Schwartz,Joanna.ChemotherapyInducedNauseaandVomiting:ThePharmacists’roleinpreventionandmanagement.”ConnecticutSocietyofHealthSystemPharmacistsAnnualMeeting,WestportCT,October30,2009.

SchwartzJ.“UpdatesinNewTreatmentsforCancer:OralChemotherapyAgents.”BarbaraM.DiLasciaLectureSeriesAnnualOncology/PainManagementSymposium,AlbanyCollegeofPharmacyandHealthSciences,Oct18,2009.

SchwartzJ.“OralChemotherapySafety.”VermontSocietyofHealthSystemPharmacists,ContinuingEducationSeminar,MontpelierVT,Nov5,2009.

SchwartzJ.“Novelcombinationchemotherapyformetastaticbreastcancer:beatingtheodds.”Hematol-ogyOncologyPharmacistAssociation.(HOPA).Miami,FL.June17,2010.

Schwartz,J.“ChemotherapyinducednauseaandVomiting:ThepharmacistsroleinDecisionMakingandManagement.”TheCaliforniaSocietyofHealthSystemPharmacists(CSHP)SeminarDay2009.DanDiego,CA,Oct3,2009.

APPOINTMENTSJeanine Abrons AbronsJ.AACPESAS-CommitteeonOrientationofNewFacultyMembers.

AbronsJ.EditorialAdvisoryBoardoftheJournaloftheAmericanPharmacistsAssociation(JAPHA).

Michael Brodeur BrodeurMR.Chair-elect.Geriatric-Sig.AmericanAs-sociationofCollegesofPharmacy.

Jessica Farrell FarrellJ.President,NortheasternChapterofNewYorkStateCouncilofHealthSystemPharmacist(NYSCHP).

FarrellJ.Member,AssociationofRheumatologyHealthProfessionals(ARHP)2010ClinicalFocusCourseTaskForce.

Gina Garrison GarrisonGD.Chair,NetworkingCommittee,Ameri-canAssociationofCollegesofPharmacy(AACP)WomenFacultySIG.2009-2010.

GarrisonGD.NewYorkStateRepresentative,ASHPStateLegislativeNetwork(2-yearterm).

GarrisonG.2009-2010NationalNominationsCommittee,RhoChiHonorSociety.

Nicole Lodise LodiseNM.AdjunctAssociateProfessor,DepartmentofMedicalEducation,AlbanyMedicalCollege.

Sarah Scarpace SarahL.Scarpace.BoardMember-at-LargefortheHe-matology/OncologyPharmacists’Association(HOPA).

Joanna Schwartz SchwartzJ.Chair,VermontSocietyofHealthSystemPharmacists(VtSHSP)ProgramCommittee.

45

POSTERS/ABSTRACTSJeanine Abrons/Tanya Vadala/ Shannon Miller/Jennifer CerulliAbronsJ,VadalaT,MillerS,CerulliJ.“EnsuringSafeMedicationDisposal.”APhAAnnualMeeting2010.JAmPharmAssoc2010;50(2);277.Abstract201.

Katie Cardone/Darren Grabe/ George Bailie CardoneKE(presenter),GiovinazzoT,ManleyHJ,GrabeDW,MeolaS,HoyCD,BailieGR.“Medica-tionregimencomplexityinpatientsreceivingdailynocturnalhomehemodialysis(DNHD).”PosteratAmericanSocietyofNephrologyRenalWeek2009,SanDiegoCA;29Oct2009.

Katie Cardone PatelK,ZhengH,CardoneKE.“Stabilitystudyofextemporaneouslypreparedsodiumthiosulfateinjections.”Posterat2010AmericanAssociationofPharmaceuticalScientistsNortheastRegionalAnnualMeeting2010,RockyHill,CT;23April2010.

Margaret Malone/John Polimeni MaloneM,AlgerS,PolimeniJ.“Dopatientstakingan-tidepressantshavethesameoneyearoutcomeaftergastricbypasssurgery?”PosteracceptedforObesity27thAnnualScientificMeeting.October2009.

Amit Pai PaiMP.“AntimicrobialDosingintheObesePatient.”InteractiveSymposium.49thInterscienceConfer-enceonAntimicrobialAgentsandChemotherapy,SanFrancisco,CA,September2009.

TsujiBT,BulittaJB,ForrestA,KelchlinPA,BrownT,HoldenPN,PaiMP,BhavnaniSM,FernandesP3,JonesRN,AmbrosePG.“PharmacokineticsPharma-codynamics(PK-PD)ofCEM102againstMethicillin-ResistantStaphylococcus aureus (MRSA)UsinganInVitroPDModel(IVPM)andMechanism-Based(MB)Modeling.”49thInterscienceConferenceonAntimi-crobialAgentsandChemotherapy,SanFrancisco,CA,September2009.

BulittaJB,OkusanyaOO,ForrestA,BhavnaniSM,ReynoldsDK,PaiMP,StillJG,FernandesP,AmbrosePG.“PopulationPharmacokinetics(PPK)ofCEM-102inHealthySubjects.”49thInterscienceConferenceonAntimicrobialAgentsandChemotherapy,SanFrancisco,CA,September2009.

VanWartSA,PaiMP,BhavnaniSM,WiegandUW,JonesRN,AmbrosePG.Pharmacokinetic-“Pharmacodynamic(PK-PD)TargetAttainment(TA)AnalysestoEvaluateSusceptibilityBreakpointsforLabeledCeftriaxone(CRO)DosingRegimens.”49thInterscienceConferenceonAntimicrobialAgentsandChemotherapy,SanFrancisco,CA,September2009.

Amy Barton Pai PaiAB,GertzbergN,NeumannP,JohnsonA.“RoleofLipotechoicacidfromStaphylococcusaureusinPathogenesisofPulmonaryEdema.”AmericanSocietyofNephrologyRenalWeek,SanDiego,CA,October30,2009.

PaiAB.“ChronicKidneyDiseasePatients(CKD3and4):ClinicalPearlsforBridgingtheGapbetweenHospitalizationandOutpatientCare.”AmericanCol-legeofClinicalPharmacyNephrologyFocusSession.Anaheim,CA,October20,2009.

GRANTSMichael Kane SPONSOR/GRANTTITLE:Lilly-Forteo/EfficacyofTeriparatideinPatientswithResolvedSecondaryHyperparathyroidismduetoVitaminDDeficiencyTERM:08/01/09-07/31/10TOTALGRANT:$22,250.00

SPONSOR/GRANTTITLE:AbbottLaboratories–AGlucoseMeterStudyTERM:09/15/09-09/14/10TOTALGRANT:$49,991.58

Thomas Lodise SPONSOR/GRANTTITLE:CubistPharmaceutical/EvaluatingtheEpidemiologyandOutcomesofPa-tientswithMRSABloodstreamInfectionsthatExpressHeteroresistancetoVancomycinTERM:06/01/10-05/31/11TOTALGRANT:$51,562.50

SPONSOR/GRANTTITLE:CubistPharmaceuticals/EvaluatingtheImpactofVancomycinMICandVancomycinExposureProfileontheOutcomesofPatientswithCA-MRSAandHCE-MRSABloodstreamInfectionsTERM:07/10/09-07/09/10TOTALGRANT:$150,640.00

Margaret Malone SPONSOR/GRANTTITLE:GlaxoSmithKline/EfficacyofOrlistat60mg(Alli)intheManagementofPre-OperativeWeighLossRequiredBeforeBariatricSurgeryTERM:08/13/09-06/15/10TOTALGRANT:$25,000.00

Amit Pai SPONSOR/GRANTTITLE:Hoffman-LaRocheInc/PharmacokineticsofOseltamivivirCarboxylateinMorbidlyObeseSubjectsTERM:01/13/10-12/31/10TOTALGRANT:$237,664.50

Katie Pallotta-Cardone SPONSOR/GRANTTITLE:Merck/ErtapenumPharma-cokineticsinPatientsonContinuousAmbulatoryPeritonealDialysisTERM:07/01/09-06/30/10

TOTALGRANT:$113,297.00

Dept. of Pharmaceutical Sciences PUBLICATIONSRichard Dearborn

ChangS,MandalaywalaNV,SnyderRG,Levendusky MC,andDearbornJrRE.Hedgehog-mediateddown-regulationofvitaminD3up-regulatedprotein1(VDUP1)precedeslaminaneurogenesis.Drosophila. Brain Res 1324:1-13,2010.(Note:thisworkwasse-lectedforthecoverart).

Voigt JM,BasleJ,PatelP,Dearborn,JrRE.InhibitionofAP-1inhumanbreastcancercellsbyVDUP1(TX-NIP).Mol Carcinog(Submitted).

KarianT,DaiY,ReedB,GrayJ,KunesS,DearbornJrRE.Reph,aregulatorofEphreceptorexpressionintheDrosophilaopticlobe.Mol Cell Neurosci(UnderRevision).

Scholarly Activity Report

Bolded nameswithincitationsindicateACPHSfacultycollaborators.

46

Levendusky MC,BasleJ,ChangS,MandalaywalaNV,Voigt JMandDearbornJrRE.Glucose-dependenteffectsonDrosophilagrowthandgliomacellsmedi-atedbyup-regulationoftheVDUP1tumorsuppres-sor.Brain Res (Re-submission).

Levendusky MC,BasleJ,ChangS,MandalaywalaNV,Voigt JM,DearbornJrRE.Expressionandregula-tionofvitaminD3up-regulatedprotein1(VDUP1)isconservedinmammalianandinsectbrain.J Comp Neurol 517:581-600,2009.

Carlos Feleder FelederC,TsengKY,CalhoonGG,O’DonnellP.Neo-natalintrahippocampalimmunechallengealtersdopaminemodulationofprefrontalcorticalinterneu-ronsinadultrats.Biol Psychiatry67:386-392,2010.

KrallCM,YaoX,Hass M,FelederC,Steiner AA.Fooddeprivationaltersthermoregulatoryresponsestolipopolysaccharidebyenhancingcryogenicinflam-matorysignalingviaprostaglandinD2. Am J Physiol Regul Integr Comp Physiol (Submitted).

Pai AB,FelederC,Johnson A.Tumornecrosisfactor-a(TNF)inducesincreasedlungvascularpermeability:aroleforGSK3α/binhibition.Amer J Physiol - Lung Cell Mol Phys. (Submitted).

VillanuevaA,YilmazMS,Millington WR,CutreraRA,StoufferDG,ParsonsLH,CheerJF,FelederC.Centralcannabinoid-1receptorantagonistadmin-istrationpreventsendotoxichypotensionaffectingnorepinephrinereleaseinthepreopticanteriorhypothalamicarea.Shock32:614-620,2009.

Gail Goodman Snitkoff BookChapterGoodman-SnitkoffG,HubbardA,BrodersJ,SchunaAA.ImmunityandAutoimmuneDisease.InWom-an’sHealth,Editors:KCalis,LHansen,MBO’Connell,JSmith.AmericanSocietyofHealthSystemPharma-cists,Bethesda,MD.2010.

Arnold Johnson Pai AB,Feleder C,JohnsonA.Tumornecrosisfactor-a(TNF)inducesincreasedlungvascularpermeability:aroleforGSK3α/binhibition.Amer J Physiol - Lung Cell Mol Phys. (Submitted).

Robert Levin Lopes LB,VanDeWallH,LiHT,VenugopalV,LiHK,NaydinS,HosmerJ,Levendusky MC,Zheng H,BentleyV,LevinR,Hass MA.TopicalDeliveryoflycopeneusingmicroemulsions:enhancedskinpenetrationandtissueantioxidantactivity.J Pharm Sci 99:1346-1357,2010.

RehfussA,SchulerC,MaxemousC,LeggettRE,LevinR.Cyclicalestrogenandfreeradicaldamagetotherabbiturinarybladder. Inter Urogynecol J21:489-494,2010.

HyderyT,JuanY,LinWY,KoganB,MannikarottuA,LeggettRE,SchulerC,LevinRM.Theeffectof2-and4-weekovariectomyonfemalerabbiturinarybladderfunction.Urology74:691-696,2009.

JuanY-S,ChuangS-M,KoganBA,MannikarottuA,HuangC-H,Leggett,RE,SchulerC,LevinRM.Effectofischemiareperfusiononbladdernerveanddetrusorcelldamage. Inter Urology Nephrology 41:513-521,2009.

JuanY,ChuangS,KoganBA,ShenJ,HuangC,WuW,LiuK,LevinRM.Ischemia/reperfusioneffectsonblad-dermuscleandmucosacellcontractileregulatoryproteins.Lower Urinary Track Symptoms1:56-61,2009.

Juan,Y-S,Chuang,SM,MannikarottuA,Chun-HsungH.,Schuler,C,Levin,RM,CoenzymeQ10diminishesischemia-reperfusioninducedapoptosisandnerveinjuryinrabbiturinarybladder,Neurourology Urody-namics.(InPress)

Juan,Y-S,Mannikarottu,ChuangSM,LiS,LinAD,Chang-ChouL,SchulerC,LeggettRE,LevinRM.ProtectiveeffectofAntrodiaCamphorataonbladderischemia/reperfusioninjury. Inter Urology Nephrology(InPress).

LinW-Y,MannikarottuA,LiS,JuanY-S,SchulerC,JavedZ,BlaivasJ,LevinRM.In-Vivocorrelationofbloodflowmeasurementswithtissuehypoxia.World J Urology(InPress).

MatsumotoS,ShimizyN,HanaiT,UemuraH,LevinRM.Bladderoutletobstructionacceleratesbladdercarcinogenesis.BJU Int(InPress).

ErcolaniM,SahotaA,SchulerC,YanM,BaroneJG,TishfieldJA,LevinRM.Bladderoutletobstructioninmalecystinuriamice. Inter Urology Nephrology(InPress).

BeanH,SchulerC,LeggettRE,Levin,RM.Antioxidantlevelsofcommonfruits,vegetables,andjuicesvs.protectiveactivityagainstin-vitroischemia/reperfu-sion. Inter Urology Nephrology (InPress).

HyderyT,SchulerC,LeggettRE,LevinRM.TreatmentofobstructivebladderdysfunctionbycoenzymeQ10andalphaLipoicacidinrabbits.Lower Urinary Track Symptoms(InPress).

RaduF,BeanH,SchulerC,LeggettRE,LevinRM.Com-parativeevaluationofantioxidantreactivitybetweenovariectomizedandcontrolurinarybladdertissueusingFRAPandCUPRACassays.Lower Urinary Track Symptoms(InPress).

TranK,LevinR,Mousa S.Reviewofbehavioralintervention,pharmacologictherapyorcombinationoftwotherapiesinthemanagementofoveractivebladder. Inter J Urol (Submitted).

JuanY-S,MannikarottuA,Chun-HsungH,LiS,SchulerC,LevinRM.TheeffectofL-arginineonbladderdys-functionfollowingovariectomy.(Submitted).

VenugopalV,RaduF,LeggettRE,AbrahamC,SchulerC,LevinRM.Effectofhydrogenperoxideonrabbiturinarybladdercitratesynthaseactivityinthepres-enceandabsenceofastandardizedgrapesuspen-sion.Int Braz J Urol(Submitted).

LinWY,ChenCS,WuCS,LinYP,LevinRM,WeiYH.Oxidativestressbiomarkersinurineandplasmaforrabbitswithpartialbladderoutletobstruction.Brit J Urol In (Submitted).

HannaK,IbrahimM,LeggettRE,LevinRM.Theeffectofcalciumontheresponseofrabbiturinarybladdermuscleandmucosatohydrogenperoxide.Urology(Submitted).

BookChapterLathersCM,LevinRM.AnimalModelforSuddenCar-diacDeath:SympatheticInnervationandMyocardialBetaReceptordensities,inSuddenDeathinEpilepsy:ForensicandClinicalIssues,Editors:C.M.Lather,Mi-chaelW.Bungo,J.E.Leetsma.Taylor&FrancisGroupLLC.(InPress)

Scholarly Activity Report

47

Luciana Lopes LopesLB,VanDeWallH,LiHT,VenugopalV,LiHK,NaydinS,HosmerJ,Levendusky M,Zheng H,BentleyV,Levin R,Hass MA.Topicaldeliveryoflycopeneusingmicroemulsions:enhancedskinpenetrationandtissueantioxidantactivity.J Pharm Sci 99:1346-1357,2010.

LopesLB,ReedR.Asimpleandrapidmethodtoassesslycopeneinmultiplelayersofskinsamples.Biomed Chromatogr.24:154-159,2010.

HosmerJ,ReedR,BentleyMV,NornooA,LopesLB.Microemulsionscontainingmedium-chainglyceridesastransdermaldeliverysystemsforhydrophilicandhydrophobicdrugs.AAPS PharmSciTech.10:589-596,2009.

LopesLB,BrophyCM,FlynnCR,YiZ-P,BowenBP,SmokeC,SealB,PanitchA,KomalavilasP.AnovelcellpermeantpeptideinhibitorofMAPKAPkinaseIIin-hibitsintimalhyperplasiainahumansaphenousveinorganculturemodel.J Vascular Surgery(Submitted).

BookChapterLopesL.Sistemasdeliberaçãoaplicadosàcosmeto-logia.In:dePaula,D.Ativoseformulaçõescosmé-ticas.EditoraUniversitária,PR,Brasil.

William Millington FilizN,BuyukuysalRL,MillingtonWR,CavunS.Glycyl-L-glutamine(β-endorphin30-31)inhibitsmorphine-induceddopamineeffluxinthenucleusaccumbens.Naunyn Schmiedebergs Arch Pharmacol (InPress).

VillanuevaA,YilmazMS,MillingtonWR,CutreraRA,StoufferDG,ParsonsLH,CheerJF,Feleder C.Centralcannabinoid-1receptorantagonistadministrationpreventsendotoxichypotensionaffectingnorepi-nephrinereleaseinthepreopticanteriorhypotha-lamicarea.Shock32:614-620,2009.

Marcel Musteata ZhanZ,MusteataFM,BassetFA,Pawliszyn.Determi-nationoffreeanddeconjugatedtestosteroneanditsmetaboliteepi-testosteroneinurineusingsolidphasemicroextraction/liquidchromatography/tan-demmassspectrometry.(Submitted)

MusteataML,MusteataFM.AnalyticalmethodsusedinconjunctionwithSPME:Areviewofrecentbioana-lyticalapplications.Bioanalysis1:1081-1102,2009.

VuckovicD,CudjoeE,MusteataFM,JanuszPawliszynJ.Automatedsolid-phasemicroextractionandthin-filmmicroextractionforhigh-throughputanalysisofbiologicalfluidsandligand–receptorbindingstudies.Nature Protocols5:140-161,2010.

Alexandre Steiner KrallCM,Yao,X,Hass M,Feleder C,SteinerAA.Fooddeprivationaltersthermoregulatoryresponsestolipopolysaccharidebyenhancingcryogenicinflam-matorysignalingviaprostaglandinD2.Am J Physiol Regul Integr Comp Physiol.2010.

SteinerAA,KrallCM,LiuE.Areappraisalontheabilityofleptintoinducefever.Physiol Behav97:430-436,2009.

SteinerAA,HunterJC,PhippsSM,NucciTB,OliveiraDL,RobertsJL,ScheckAC,SimmonsDL,RomanovskyAA.Cyclooxygenase-1or-2:whichonemediateslipopolysaccharide-inducedhypothermia?Am J Physiol Regul Integr Comp Physiol297:R485-R494,2009.

RomanovskyAA,AlmeidaMC,GaramiA,SteinerAA,NormanMH,MorrisonSF,NakamuraK,BurmeisterJJ,NucciTB.Thetransientreceptorpotentialvanilloid-1channelinthermoregulation:athermosensoritisnot.Pharmacol Rev61:228-261,2009.

BookChapterTranslationofbookfromEnglishtoPortuguese:Physiologyandpathophysiologyoftemperatureregulation(BlatteisCM,Editor;SteinerAA,BicegoKC,AlmeidaMC,translators).EdUSP,SãoPaulo,inpress.(Inpress)

Jeffrey Voigt VoigtJM,BasleJ,PatelP,Dearborn, Jr RE.InhibitionofAP-1inhumanbreastcancercellsbyVDUP1(TX-NIP).Mol Carcinog (Submitted).

Levendusky MC,BasleJ,ChangS,MandalaywalaNV,VoigtJMandDearborn Jr RE.Glucose-dependenteffectsonDrosophilagrowthandgliomacellsmedi-atedbyup-regulationoftheVDUP1tumorsuppres-sor.Brain Res(Re-submission).

Levendusky MC,BasleJ,ChangS,MandalaywalaNV,VoigtJM,Dearborn Jr RE.Expressionandregula-tionofvitaminD3up-regulatedprotein1(VDUP1)isconservedinmammalianandinsectbrain.J Comp Neurol517:581-600,2009.

HaiAn Zheng LopesLB,VanDeWallH,LiHT,VenugopalV,LiHK,NaydinS,HosmerJ,LevenduskyM,ZhengH,BentleyV, Levin R,Hass MA.Topicaldeliveryoflycopeneusingmicroemulsions:enhancedskinpenetrationandtissueantioxidantactivity.J Pharm Sci 99:1346-1357,2010.

BookChapterSinkoP(Editor),AmidonGE,MiddaughCR,OmidianH,ParkK,SiahaanTJ,SinghY,ZhengH(Contributors).Martin’s Physical Pharmacy and Pharmaceutical Sci-ences, 6th edition.LippincottWilliams&Wilkins,2010.

PRESENTATIONS AND ABSTRACTSRichard Dearborn Voigt JM,BajariaA,DearbornJrRE.“RegulationofVDUP1ExpressioninBreastCancerCellsbyCyclo-pamine.”AmericanAssociationforCancerResearchAnnualMeeting.Washington,DC;April2010.

ChangS,WrightK,WhiteC,YoussefS,Dearborn,Jr,RE.“VitaminD3up-regulatedprotein1(VDUP1)tumorsuppressorfunctionduringlarvalneuroblastproliferationanddifferentiation.”ColdSpringHarborNeurobiologyofDrosophilaMeeting.ColdSpringHarbor,NY;Sept.30–Oct.3,2009.

LiHT,Lopes L,Zheng H,Hass MA,DearbornJrRE,Voigt JM.“Research-basedInstructionalLaboratoryforaPharmaceuticalAnalyticalTechniquesCourse.”AACPAnnualMeetingandSeminars.Boston,MA;July18-22,2009.

DearbornJrRE.“VDUP1TumorSuppressorFunctioninCNSDevelopment:RegulationofCellDifferentia-tion,ProliferationandNeuralStemCellFate.”AlbanyCollegeofPharmacyandHealthSciences.Albany,NY;February5,2010.

Bolded nameswithincitationsindicateACPHSfacultycollaborators.

48

DearbornJrRE.“WhatDeterminesBrainSize?”OpenHouseLecture.AlbanyCollegeofPharmacyandHealthSciences.Albany,NY;November15,2009.

Carlos Feleder YilmazMS,FelederCandMillington WR.“Cannabi-noid-1ReceptorBlockadeintheMidbrainPeriaque-ductalGrayRegionpreventsthehypotensionevokedbylipopolysaccharide.“SocNeurosci.Chicago,IL;Oct.17–21,2009.

Arnold Johnson Barton-Pai A,GertzbergN,NeumannP,JohnsonA.“LipoteichoicAcidfromStaphylococcusaureusCausesLungEndothelialBarrierDysfunction.”Ameri-canSocietyofNephrologyRenalWeek.SanDiego,CA;October31,2009.

Barton-Pai A,Bailie GandJohnsonA.“EffectsofIntravenousIronProductsinthePathogenesisofPulmonaryEdema,”XLVIIERA-EDTACongress,IIDGfNCongress.Munich,Germany;June25-28,2010.

JohnsonA,Barton-Pai A.“Lipoteichoicacid(LTA)CausesReactiveOxygenSpecies(ROS)DependentLungEndothelialBarrierDysfunction.”AmericanTho-racicSociety.NewOrleans,LA;May14-18,2010.

Robert Levin RehfussA,SchulerC,MaxemousC,LeggettRE,LevinRM.“Effectofcyclicalestrogenonthefemaleurinarytractofrabbits.”UrologicalResearchSociety.PortDouglasAustralia;August10-14,2009.

Lopes LB,VandewallH,LiHT,VenugopalV,LiHK,NaydinS,HosmerJ,BentleyVLB,LevenduskyM,Hass MA,LevinR,Zheng H.“TopicalDeliveryofLycopeneusingMicroemulsions.”7thCongressofPharmaceu-ticalSciencesofRibeiraoPreto.RibeiraoPreto,SP,Brazil;September6-9,2009.

ErcolaniM,SahotaA,SchulerC,YanM,BaroneJG,TishfieldJA,LevinRM.“TheEffectsofCystinuriaonBladderContractilityandHistologyintheSlc3a1KnockoutMouse–NewInsightsfortheManage-mentofPediatricCystinuria.”AmericanAssociationofPediatrics.NewYork,NY;October17-19,2009.

Luciana Lopes HosmerJ,ShinSH,NornooA,Zheng H,LopesLB.“InfluenceoftheLiquidCrystallineStructureontheInVitroReleaseandSkinPenetrationofanAnticancerDrug.”AAPSNortheastRegionalAnnualMeeting.RockyHill,CT;April23,2010.

NgW,LopesLB.“DevelopmentofSodiumAlginateBeadsContainingVariedLipidRatiosforWoundHeal-ing.”AAPSNortheastRegionalAnnualMeeting.RockyHill,CT;April23,2010.

ShinS,LopesL,Zheng H.“StabilityandAntioxidantActivityofLycopeneMicroemulsions.”AAPSNorth-eastRegionalAnnualMeeting.RockyHill,CT;April23,2010.

LiHT,LopesL,Zheng H,Hass MA,Dearborn Jr RE,Voigt JM.“Research-basedInstructionalLaboratoryforaPharmaceuticalAnalyticalTechniquesCourse.”AACPAnnualMeetingandSeminars.Boston,MA;July18-22,2009.

LopesLB,VandewallH,LiHT,VenugopalV,LiHK,NaydinS,HosmerJ,BentleyVLB,LevenduskyM,Hass MA,Levin R,Zheng H.“TopicalDeliveryofLycopeneusingMicroemulsions.”7thCongressofPharmaceuticalSciencesofRibeiraoPreto.RibeiraoPreto,SanPaolo,Brazil;September6-9,2009.

NornooA,Bennettl,LopesL.“InvestigatingtheRoleofMicroemulsionsinthePermeabilityofCytotoxicAgentsUsingaCaco-2CellModel.”7thCongressofPharmaceuticalSciencesofRibeiraoPreto.RibeiraoPreto,SanPaolo,Brazil;September6-9,2009.

HosmerJ,NornooA,LopesLB.“DevelopmentofLiquidCrystallinePhasesforTopicalDeliveryofPacli-taxel.”36thAnnualMeetingoftheControlledReleaseSociety.Copenhagen,Denmark;July18-22,2009.

William Millington YilmazMS,Feleder C,MillingtonWR.“Cannabinoid-1ReceptorBlockadeintheMidbrainPeriaqueductalGrayRegionpreventsthehypotensionevokedbylipopolysaccharide.”SocNeurosci.Chicago,IL;Oct17-21,2009.

Marcel Musteata MusteataMF.Exploring“ApplicationsofMicrosam-plingandMicroextractioninPharmacokinetics.”AAPSNortheastRegionalDiscussionGroup.RockyHill,CT;April23,2010.

VuckovicD,deLannoyI,GienB,YingboYangY,MusteataMF,ShireyRE,SidiskyL,PawliszynJ.“InVivoSolid-phaseMicroextractionforPharmacokineticsStudiesinMice:ComparisontoManualTerminalandAutomatedSerialSampling.”PittsburghConference(Pittcon).Orlando,FL;March2010.

Michael Raley Snitkoff GG,RaleyM.“UseofPeer-ledWorkshopsinanIntegratedPharmDProgram.”AACPAnnualMeet-ing.Boston,MA;July19-22,2009.

Gail G. Snitkoff SnitkoffGG,Raley M.“UseofPeer-ledWorkshopsinanIntegratedPharmDProgram.”AACPAnnualMeet-ing.Boston,MA;July19-22,2009.

Alexandre Steiner SteinerAA.“Feverversusanapyrexia:letthebattlebegin.”AutonomicNeuroscience(specialissue:6thCongressoftheInternationalSocietyforAutonomicNeuroscience)149:52,2009

LiuE,KrallCM,SteinerAA.“Areappraisalontheabilityofleptintoinducefever.”In:NewEnglandScienceSymposium.Boston,MA;ProgramNo.25,2010.

SteinerAA.“ChangingtheGame:FromFevertoHy-pothermiainSystemicInflammation.”SeminarsoftheGraduatePrograminPhysiology,UniversityofSaoPauloMedicalSchool,RibeiraoPreto,Brazil;January12,2010.

Jeffrey Voigt LiHT,Lopes L,Zheng H,Hass MA,Dearborn Jr RE,VoigtJM.“Research-basedInstructionalLaboratoryforaPharmaceuticalAnalyticalTechniquesCourse.”AACPAnnualMeetingandSeminars.Boston,MA;July18-22,2009.

VoigtJM,BajariaA,Dearborn Jr RE.“RegulationofVDUP1ExpressioninBreastCancerCellsbyCyclo-pamine.”AmericanAssociationforCancerResearchAnnualMeeting.Washington,DC;April2010.

49

HaiAn Zheng HosmerJ,ShinSH,NornooA,ZhengH,Lopes LB.“Influenceoftheliquidcrystallinestructureontheinvitroreleaseandskinpenetrationofananticancerdrug.”AAPSNortheastRegionalAnnualMeeting.RockyHill,CT;April23,2010.

ShinSH,Lopes LB,ZhengH.“StabilityandAntioxi-dantActivityofLycopeneMicroemulsions.”AAPSNortheastRegionalAnnualMeeting.RockyHill,CT;April23,2010.

TasgaonkarR,AzizJ,SgourakisNG,TianJ,GarciaAE,ZhengH.“Computersimulationofinsulinmolecu-lardynamicsinpharmaceuticalformulation.”AAPSNortheastRegionalAnnualMeeting;RockyHill,CT;April23,2010.

PatelK,ZhengH,Cardone K.“StabilityStudyofExtemporaneouslyPreparedSodiumThiosulfateInjections.”AAPSNortheastRegionalAnnualMeeting.RockyHill,CT;April23,2010.

Lopes LB,VandewallH,LiHT,VenugopalV,LiHK,NaydinS,HosmerJ,BentleyVLB,Levendusky M,Hass, MA,Levin R,ZhengH.“TopicalDeliveryofLycopeneusingMicroemulsions.”7thCongressofPharmaceuticalSciencesofRibeiraoPreto.RibeiraoPreto,SP,Brazil;September6-9,2009.

LiHT,Lopes L,ZhengH,Hass MA, Dearborn JR RE,Voigt JM.“Research-basedInstructionalLaboratoryforaPharmaceuticalAnalyticalTechniquesCourse.”AACPAnnualMeetingandSeminars.Boston,MA;July18-22,2009.

GRANTSStefan Balaz SPONSOR/GRANTTITLE:NIH/ConceptualPredictionofDrugBioactivitiesinCell-BasedAssays:cell-QSARTERM:09/01/09-08/31/14TOTALGRANT:$1,347,500.00

Arnold Johnson SPONSOR/GRANTTITLE:NIH/NationalLung/BloodInstitute/AMechanismforTNFInducedEndothelialDysfunctionTERM:05/01/10-04/30/14TOTALGRANT:$1,405,380.00

Robert Levin SPONSOR/GRANTTITLE:VaginallyDeliveredOxybu-tyninonBladderandSystemicCholonergicFunctionTERM:10/01/09-12/31/09TOTALGRANT:$9,875.00

SPONSOR/GRANTTITLE:Astellas/SynergyofSolif-enacinintheTreatmentofExperimentalOveractiveBladderDysfunctionbyAntioxidantSupplementsTERM:07/27/09-01/26/11TOTALGRANT:$82,275.00

Pharmaceutical Research Institute PUBLICATIONSShaker Mousa TranK,Levin RM,MousaSA.BehavioralInterventionversusPharmacotherapyorTheirCombinationsintheManagementofOveractiveBladderDysfunction.AdvUrol.2009:345324.Epub2009Dec15.

AderinwaleOG,ErnstHW,MousaSA.CurrenttherapiesandnewstrategiesforthemanagementofAlzheimer’sdisease.Am J Alzheimers Dis Other Demen2010;25:414-24.

AljadaA,DongL,MousaSA.Sirtuin-targetingdrugs:Mechanismsofactionandpotentialtherapeuticap-plications.Curr Opin Investig Drugs2010;11:1158-68.

AmirkhosraviA,MousaSA,AmayaM,MeyerT,DavilaM,RobsonT,etal.Assessmentofanti-metastaticeffectsofanticoagulantandantiplateletagentsus-inganimalmodelsofexperimentallungmetastasis.Methods Mol Biol 2010;663:241-59.

Assimon MM,MousaSA,ShakerO,Pai AB.Theeffectofsevelamerhydrochlorideandcalcium-basedphosphatebindersonmortalityinhemodialysispatients:aneedformoreresearch.Consult Pharm 2010;25:41-54.

AwadOI,TraversGEandMousaSA.DrugDisposal:CurrentRecommendationsandEnvironmentalCon-cerns. Int J Pharm Research 2010;Volume2,Issue4

BharaliDJ,MousaSA.Emergingnanomedicinesforearlycancerdetectionandimprovedtreatment:cur-rentperspectiveandfuturepromise.Pharmacol Ther 2010;128:324-35.

BlockRC,DuffR,LawrenceP,KakinamiL,BrennaJT,ShearerGC,etal.TheeffectsofEPA,DHA,andaspiriningestiononplasmalysophospholipidsandautotaxin.Prostaglandins Leukot Essent Fatty Acids 2010;82:87-95.

BridouxA,CuiH,DyskinE,SchmitzerAR,YalcinM,MousaSA.Semisynthesisandpharmacologicalactivitiesofthyroxineanalogs:Developmentofnewangiogenesismodulators.Bioorg Med Chem Lett 2010;20:3394-8.

DavisPJ,ZhouM,DavisFB,Lansing L,MousaSA,LinHY.Mini-review:Cellsurfacereceptorforthyroidhormoneandnongenomicregulationofionfluxesinexcitablecells.Physiol Behav2010;99:237-9.

JacobyDB,DyskinE,YalcinM,KesavanK,DahlbergW,RatliffJ,etal.Potentpleiotropicanti-angiogeniceffectsofTM601,asyntheticchlorotoxinpeptide.Anticancer Res2010;30:39-46.

LinY,MousaSS,ElshourbagyN,MousaSA.Currentstatusandfuturedirectionsinlipidmanagement:emphasizinglow-densitylipoproteins,high-densitylipoproteins,andtriglyceridesastargetsfortherapy.VascHealthRiskManag2010;6:73-85.

LuidensMK,MousaSA,DavisFB,LinHY,DavisPJ.Thyroidhormoneandangiogenesis.Vascul Pharma-col 2010;52:142-5.

MousaSA,AlMomenA,AlSayeghF,AlJaouniS,NasrullahZ,AlSaeedH,etal.Managementofpainfulvaso-occlusivecrisisofsickle-cellanemia:consensusopinion.ClinApplThrombHemost2010;16:365-76.

MousaSA,JeskeWP,FareedJ.Antiplatelettherapyprasugrel:anovelplateletADPP2Y12receptoran-tagonist.Clin Appl Thromb Hemost 2010;16:170-6.

MousaSA,JeskeWP,FareedJ.Prasugrel:anovelplate-letADPP2Y(12)receptorantagonist.Methods Mol Biol2010;663:221-8.

Scholarly Activity Report

Bolded nameswithincitationsindicateACPHSfacultycollaborators.

50

MousaSA,MousaSS.Currentstatusofvascularendo-thelialgrowthfactorinhibitioninage-relatedmaculardegeneration.BioDrugs 2010;24:183-94.

MousaSA,QariMH.Diagnosisandmanagementofsicklecelldisorders.Methods Mol Biol 2010;663:291-307.

MousaSA,SudhaT,DyskinE,DierU,GallatiC,HankoC,etal.Stressresistanthumanembryonicstemcellsasapotentialsourcefortheidentificationofnovelcancerstemcellmarkers.Cancer Lett 2010;289:208-16.

MousaSA.Adhesionmolecules:potentialtherapeuticanddiagnosticimplications.Methods Mol Biol2010;663:261-76.

MousaSA.Antiplatelettherapies:druginteractionsinthemanagementofvasculardisorders.Methods Mol Biol2010;663:203-19.

MousaSA.Antithromboticeffectsofnaturallyderivedproductsoncoagulationandplateletfunction.Meth-ods Mol Biol 2010;663:229-40.

MousaSA.Heparinandlow-molecularweightheparinsinthrombosisandbeyond.Methods Mol Biol 2010;663:109-32.

MousaSA.Invitromethodsofevaluatingantithrom-boticsandthrombolytics.Methods Mol Biol 2010;663:1-28.

MousaSA.Invivomodelsfortheevaluationofantithromboticsandthrombolytics.Methods Mol Biol 2010;663:29-107.

MousaSA.Novelanticoagulanttherapy:principleandpractice.Methods Mol Biol2010;663:157-79.

MousaSA.OraldirectfactorXainhibitors,withspecialemphasisonrivaroxaban.Methods Mol Biol 2010;663:181-201.

MousaSA.Pharmacogenomicsinthrombosis.Meth-ods Mol Biol 2010;663:277-89.

MousaSS,DavisFB,DavisPJ,MousaSA.Humanplate-letaggregationanddegranulationisinducedinvitrobyL-thyroxine,butnotby3,5,3’-triiodo-L-thyronineordiiodothyropropionicacid(DITPA).Clin Appl Thromb Hemost2010;16:288-93.

RofaielS,MuoENandMousaSA.PharmacogenomicsinBreastCancer:StepstowardPersonalizedMedicineinBreastCancerManagement.Pharmacogenom Personalized Med;Sept2010:3Pages129–143.

MousaSA,MousaSS.Currentstatusofvascularendo-thelialgrowthfactorinhibitioninage-relatedmaculardegeneration.BioDrugs.2010Jun;24(3):183-94.

MousaSA,SudhaT,DyskinE,DierU,GallatiC,HankoC,ChitturSV,RebbaaA.Stressresistanthumanembryonicstemcellsasapotentialsourcefortheidentificationofnovelcancerstemcellmarkers.Cancer Lett.2010Mar28;289(2):208-16.

UsoroOB,MousaSA.VitaminEformsinAlzheimer’sdisease:areviewofcontroversialandclinicalexperi-ences.Crit Rev Food Sci Nutr 2010;50:414-9.

YalcinM,BharaliDJ,DyskinE,DierE,Lansing L,MousaSS,etal.Tetraiodothyroaceticacidandtetraiodothyroaceticacidnanoparticleeffectivelyinhibitthegrowthofhumanfollicularthyroidcellcarcinoma.Thyroid2010;20:281-6.

YalcinM,DyskinE,Lansing L,BharaliDJ,MousaSS,BridouxA,etal.Tetraiodothyroaceticacid(tetrac)andnanoparticulatetetracarrestgrowthofmedul-larycarcinomaofthethyroid.J Clin Endocrinol Metab 2010;95:1972-80.

Abdel-MajeedS,MohammadA,ShaimaAB,Moham-madR,MousaSA.Inhibitionpropertyofgreenteaextractinrelationtoreserpine-inducedribosomalstripsofroughendoplasmicreticulum(rER)oftheratkidneyproximaltubulecells. J Toxicol Sci. 2009Dec;34(6):637-45.

KatrychO,SimoneTM,AzadS,MousaSA.Disease-ModifyingAgentsintheTreatmentofMultipleScle-rosis:AReviewofLong-TermOutcomes.CNS Neurol Disord Drug Targets. 2009Dec;8(6):512-9.

KempMM,KumarA,MousaS,DyskinE,YalcinM,AjayanP,LinhardtRJ,MousaSA.Goldandsilvernanoparticlesconjugatedwithheparinderivativepossessanti-angiogenesisproperties.Nanotechnol-ogy.2009Nov11;20(45):455104.

RebbaaA,ChuF,SudhaT,GallatiC,DierU,DyskinE,YalcinM,BianchiniC,ShakerO,MousaSA.TheAnti-angiogenicActivityofNSITC,aSpecificCathepsinLInhibitor.Anticancer Res.2009Nov;29(11):4473-81.

GlinskiiAB,GlinskyGV,LinHY,TangHY,SunM,DavisFB,LuidensMK,MousaSA,HercbergsAH,DavisPJ.Modificationofsurvivalpathwaygeneexpressioninhumanbreastcancercellsbytetraiodothyroaceticacid(tetrac).Cell Cycle. 2009Nov1;8(21):3554-62.

KempMM,KumarA,MousaS,DyskinE,YalcinM,AjayanP,LinhardtRJ,MousaSA.Goldandsilvernanoparticlesconjugatedwithheparinderivativepossessanti-angiogenesisproperties.Nanotechnol-ogy2009Nov11;20(45):455104.

DuongA,MousaSA.CurrentstatusofnucleosideantiviralsinchronichepatitisB.Drugs Today(Barc).2009Oct;45(10):751-61.

YalcinM,BharaliDJ,Lansing L,DyskinE,MousaSS,HercbergsA,DavisFB,DavisPJ,MousaSA.Tetraido-thyroaceticacid(tetrac)andtetracnanoparticlesinhibitgrowthofhumanrenalcellcarcinomaxeno-grafts.Anticancer Res. 2009Oct;29(10):3825-31.

MousaSA,PetersenLJ.Anti-cancerpropertiesoflow-molecular-weightheparin:preclinicalevidence.Thromb Haemost.2009Aug;102(2):258-67.

SuwanJ,ZhangZ,LiB,VongchanP,MeepowpanP,ZhangF,MousaSA,MousaS,PremanodeB,Kong-tawelertP,LinhardtRJ.Sulfonationofpapain-treatedchitosananditsmechanismforanticoagulantactiv-ity.Carbohydr Res. 2009Jul6;344(10):1190-6.

AlsayeghF,Al-RasheedM,Al-MuhainiA,Al-HumoudE,Al-OstazM,MousaSA.Heparinanticoagulationresponsivenessinacoronarycareunit:aprospectiveobservationalstudy.Cardiovasc Ther. 2009Summer;27(2):77-82.

KempMM,KumarA,ClementD,AjayanP,MousaSA,LinhardtRJ.Hyaluronan-andheparin-reducedsilvernanoparticleswithantimicrobialproperties.Nano-medicine2009;4(4):421-9.

MousaSS,DavisFB,DavisPJ,MousaSA:HumanPlateletAggregationandDegranulationIsInducedInVitrobyL-Thyroxine,butNotby3,5,3’-Triiodo-L-ThyronineorDiiodo-thyropropionicAcid(DITPA).Clin Appl Thromb Hemost. 2010Jun;16(3):288-93.

DennisT,FanousM,MousaSA.Naturalproductsforchemopreventiveandadjunctivetherapyinonco-logicdisease.Nutr Cancer. 2009;61(5):587-97.

Scholarly Activity Report

51

DavisPJ,DavisFB,LinHY,MousaSA,ZhouM,LuidensMK.Translationalimplicationsofnongenomicactionsofthyroidhormoneinitiatedatitsintegrinreceptor.Am J Physiol Endocrinol Metab.2009;297(6):E1238-46.

BharaliDJ,KhalilM,GurbuzM,SimoneTM,MousaSA.Nanoparticlesandcancertherapy:aconcisereviewwithemphasisondendrimers.Int J Nanomedicine. 2009;4(1):1-7.

AriasHR,RichardsVE,NgD,GhafooriME,LeV,MousaSA.Roleofnon-neuronalnicotinicacetylcholinereceptorsinangiogenesis.Int J Biochem Cell Biol. 2009;41(7):1441-51.

AljadaA,ShahKA,MousaSA.Peroxisomeproliferator-activatedreceptoragonists:dotheyincreasecardio-vascularrisk?PPAR Res.2009;2009:460-764.

BaroneC,MousaSS,MousaSA.Pharmacoenomicsincardiovasculardisorders:Stepsinapproachingpersonalizedmedicineincardiovascularmedicine.Pharmacogenomics and Personalized Medicine 2009:2:1-9.

GreeneR,MousaSS,ArdawiM,QariM,MousaSA.Pharmacogenomicsinosteoporosis:Stepstowardpersonalizedmedicine.Pharmacogenomics and Personalized Medicine2009:21-10.

ClarkeH,MousaSA.Theimplicationsofpharma-cogenomicsinthetreatmentofHIV-1-infectedpatientsofAfricandescent.Pharmacogenomics and Personalized Medicine2009:293-99.

AveryP,MousaSS,MousaSA.PharmacogenomicsintypeIIdiabetesmellitusmanagement:Stepstowardpersonalizedmedicine.PharmacogenomicsandPersonalizedMedicine2009:21-13.

GRANTSShaker Mousa SPONSOR/GRANTTITLE:RPINIHSubAward-DevelopmentofBiengineeredHeparinFromaNon-AnimalSourceTERM:08/01/09-04/30/14TOTALGRANT:$654,500.00

SPONSOR/GRANTTITLE:VascularVisionPharmaceut-cials-NovelModulatorsofHDLMetabolismTERM:07/27/09-07/26/10TOTALGRANT:$75,000.00

SPONSOR/GRANTTITLE:UniversityofWisconsin-DODSubAward-SustainedReleaseOralNanoformulatedGreenTeaforProstateCancerPreventionTERM:04/15/10-04/14/11TOTALGRANT:$40,501.00

SPONSOR/GRANTTITLE:NIH/Site-directedChemotherapyforBreastCancerUsingNovelAngio-genesisInhibitorTERM:08/07/09-07/31/11TOTALGRANT:$372,680.00

Dept. of Health Sciences PUBLICATIONSMagdalene Assimon Assimon,MM,Salenger,PV,El-Fawal,HAN,Mason, DL.CharacterizationofErgocalciferolsupplementa-tiononvascularadhesionmoleculesandoxidativeLDLinhemodialysispatients.Am. J. Nephrology (submitted).(2010).

Indra Balachandran BalachandranI,WalkerJ,TaylorJ,etal:TheimpactofNewYorkState’snewlicensurelegislationforlabora-toryprofessionalsonhealthcareproviders:Resultsofasurveyonissuesrelatedtostaffingofclinicallabora-tories,Journal of Allied Health,Dec2009,113E-117E.

BalachandranI.TransformationinEducationandPractice:CytotechnologyProgram,AlbanyCollegeofPharmacy&HealthSciences,Albany,N.Y.ASC Bulletin,2010,XLVII(4):94-95.

BalachandranI,WalkerJ,BromanJ:FineNeedleAspi-rationCytologyofALK1(-),CD30(+)AnaplasticLargeCellLymphomaPostRenalTransplantation–ACaseReportandliteraturereview.Diagnostic Cytopathol-ogy,2009doi:10.1002/dc21176.

BalachandranI,JiayuhJu,WalkerJ,BromanJ:Fineneedleaspirationofmetastaticgranulosacelltumoroftheovary.AcceptedforpublicationinActa Cyto-logica,Feb.2010.

Lawrence Lansing YalcinM,BharaliDJ,DyskinE,DierE,LansingL,MousaSS,DavisFB,DavisPJ,Mousa SA.Tetraiodothyroace-ticacidandtetraiodothyroaceticacidnanoparticleeffectivelyinhibitthegrowthofhumanfollicularthyroidcellcarcinoma.Thyroid.2010Mar;20(3):281-6.

YalcinM,DyskinE,LansingL,BharaliDJ,MousaSS,BridouxA,HercbergsAH,LinHY,DavisFB,GlinskyGV,GlinskiiA,MaJ,DavisPJ,Mousa SA.Tetraiodothyro-aceticAcid(Tetrac)andNanoparticulateTetracArrestGrowthofMedullaryCarcinomaoftheThyroid.J Clin Endocrinol Metab.2010Feb4.[Epubaheadofprint]

YalcinM,BharaliDJ,LansingL,DyskinE,MousaSS,HercbergsA,DavisFB,DavisPJ,Mousa SA.Tetraiodo-thyroaceticacid(tetrac)andtetracnanoparticlesinhibitgrowthofhumanrenalcellcarcinomaxeno-grafts.Anticancer Res.2009Oct;29(10):3825-31.

ARTICLE REVIEWSLawrence Lansing DavisPJ,ZhouM,DavisFB,LansingL,Mousa SA,LinHY.Mini-review:Cellsurfacereceptorforthyroidhormoneandnongenomicregulationofionfluxesinexcitablecells.Physiol Behav. 2010Feb9;99(2):237-9.

BOOK CHAPTERSHassan El-Fawal El-Fawal,H.A.N.Neurotoxicity:Commonthemesandbiomarkers.Encyclopedia of Environmental Health.(S.Ansar,ed).ElseviersPublishing,London,UK.(inpressfor2010).

ABSTRACTS/PRESENTATIONS & EXHIBITSIndra Balachandran BalachandranI.,WalkerJ.“DevelopmentofanAsyn-chronousReviewCourseinCytopathology.”FacultyDevelopmentSeries,AlbanyCollegeofPharmacyandHealthSciences,March30,2010.

Bolded nameswithincitationsindicateACPHSfacultycollaborators.

52

MENTORING STUDENTS TO PRESENT AT NATIONAL MEETINGSLindsay Ruslander CasepresentationattheASCTmeeting,Spring,2010.

Julie Deluca, Rachel Desanto, Ken Ibe, Sierra Kovar, Lisa Lavery, Jennifer Lemay, Caitlin Len-nox, Lany Mulyana, Deepika Narahari, and John OrfanidesPresentedcasesincomputerformat.

Sierra Kovar Wonprizeforbestcomputerpresentation.

PROFESSIONAL ACTIVITIES - SCIENTIFIC/CLINICAL/PR NATIONALIndra Balachandran AmericanSocietyCytotechnology,InvitedSpeaker,November2009.Florida.

Dept. of Arts and Sciences PEER REVIEWED ARTICLESPatricia Baia Baia,P.NoMoneyforProfessionalDevelopment?GoLocal.Educause Quarterly Magazine,v32(2),2009.

Trent Gemmill Singh,N;Ma,Z.;Gemmill,T.;Wu,X;DeFiglio,H;Ros-settini,A;Rabeler,C;Beane,O;Morse,R;Palumbo,M;andHanes,SD.TheEss1ProlylIsomeraseIsRequiredforTranscriptionTerminationofSmallNoncodingRNAsviatheNrd1Pathway.MolecularCell,Volume36,Issue2,255-266,23October2009.

Martha Hass Lopes, LB;VanderMall,H.;Li,HT;Venugopal,V.;Li,HK;Naydin,S.;Hosmer,J.;Bentley,M.V.L.B.;Levendusky, M.;Hass,MA.Topicaldeliveryoflycopeneusingmi-croemulsions:enhancedskinpenetrationandtissueantioxidantactivity.J. Pharm Sci.99(3)1346-57,2010.

Levin, RM.;Legget,RE;Schuler,C.;Rehfuss,A.;Hass,MA.OxidativeStressandLowerUrinaryTractDysfunctionsPrimarilyFoundinWomen.Urol Sci. 1(1)7-17.2010.

Krall,C.M.;Yao,X.;Hass,MA;Feleder, C.;Steiner, A.A.FooddeprivationaltersthermoregulatoryresponsestolipopolysaccharidebyenhancingcryogenicinflammatorysignalingviaprostaglandinD2.Am J Physiol Regul Integr Comp Physiol 298:R1512-R1521,2010.

Susan Ludeman Pinto,N,Ludeman,SM,DolanME.PharmacogeneticStudiesRelatedtoCyclophosphamide-BasedThera-py.Pharmacogenomics10(12),1897-1903(2009).

Amoyaw,P.N.A.a;Springer,J.B.b#;Gamcsik,M.P.c;Mutesi,R.L.b;D’Alessandro,M.A.d;Dempsey,C.R.a;andLudeman,S.M.a*.Synthesisof13C-LabelledDe-rivativesofCysteineforMagneticResonanceImagingStudiesofDrugUptakeandConversiontoGlutathi-oneinRatBrain.Journal of Labelled Compounds and Radiopharmaceuticals.

Meenakshi Malik Noah,C.E.,Malik,M.,Bublitz,D.C.,Camenares,D.,Sellati,T.J.,Benach,J.L.,Furie,M.B.GroELandlipopolysachharidefromFrancisellatularensislivevaccinestrainsynergisticallyacti-vatehumanmacrophages. Infection and Immunity 78(4):1797-806(2010).

Melillo,A.A.,Mahawar,M.,Sellati,T.J.,Malik,M.,Metzger,D.W.,Melendez,J.A.,andBakshi,C.S.IdentificationofFrancisellatularensislivevaccinestrainCuZnsuperoxidedismutaseascriticalforre-sistancetoextracellularlygeneratedreactiveoxygenspecies. J.Bacteriol. 191(20):6447-56(2009).

Wendy Parker London,A.S.andParker,W.M.IncarcerationandPost-IncarcerationLivingArrangements:FindingsfromtheNationalHealthandSocialLifeSurvey.Journal of Family Issues.30(6):787-812,2009.

Michael Racz Racz,MJ,SedranskJ.Bayesianandfrequentistmeth-odsforproviderprofilingusingrisk-adjustedassess-mentsofmedicaloutcomes. Journal of the American Statistical Association105,48-58,2010.

Hannan,EL,RaczMJ,GoldJ,CozzensK,StamatoNJ,PowellT,HibberdM,WalfordG.AdherenceofcatheterizationlaboratorycardiologiststoAmericanCollegeofCardiology/AmericanHeartAssociationguidelinesforpercutaneouscoronaryinterventionsandcoronaryarterybypassgraftsurgery:whathap-pensinactualpractice?,Circulation121,267-752010.

HannanEL,ZhongY,RaczMJ,JacobsAK,WalfordG,CozzensK,HolmesDR,JonesRH,HibberdM,DoranD,WhalenD,KingSB3rd.OutcomesforpatientswithST-elevationmyocardialinfarctioninhospitalswithandwithoutonsitecoronaryarterybypassgraftsurgery:theNewYorkStateexperience.Circulation: Cardiovascular Interventions2,519-27,2009.

Laura Rogers Rogers,L.DivingintoPrisonTeaching:MinaShaugh-nessy,TeacherDevelopment,andtheRealitiesofPrisonWriting.Reflections:A Journal of Writing, Service Learning and Community Literacy8(3):Sum-mer200999-121.

BOOK CHAPTERSKevin Hickey Hickey,K.“AfricaandTravelWriting.”NewDirectionsinTravelWritingandTravelStudies.Ed.CarmenAndras.Aachen:ShakerPublishingGmbH,103-118,2010.

REVIEW ARTICLESKenneth Blume Blume,K.ReviewofCraigL.Symonds,LincolnandhisAdmirals.AbrahamLincoln,theU.S.Navy,andtheCivilWar.(NewYork:OxfordUniversityPress,2008)forInternational Journal of Maritime History,Decem-ber2009.

Blume,K.Reviewof The Sherlock Holmes Illustrated Cyclopedia of Nautical Knowledge,byWalterW.Jaffee.(PaloAlto,CA:GlencannonPress,2009),forSteamboat Bill,thequarterlyjournaloftheSteamshipHistoricalSocietyofAmerica,Winter2009/2010.

53

POSTER PRESENTATIONS/ EXHIBITIONSPatricia Baia Baia,P.“Createyourownprofessionaldevelopmentopportunity.”ConferenceonInstructionalTechnology(CIT),Plattsburgh,NY,2010.

Lynn Evans Werner,E.A.,Evans,L.,Monk,C.“Higherantenatalmaternalcortisolassociatedwithmorereactiveinfanttemperament–butonlywhenmaternalageiscon-trolledfor.”XVIIthBiennialInternationalConferenceonInfantStudies,2010.

Evans,L.,Werner,E.A.,Russo,J.,Ju,J.,Monk,C.“Pre-schooltemperamentmeasuresandthe5-HTTLPR,DRD4,ACEandBDNFpolymorphisms:apilotstudy.”XVIIWorldCongressonPsychiatricGenetics,Balti-more,MD,2009.

Evans,L.,Werner,E.A.,Russo,J.,Ju,J.,Monk,C.“ABDNFvariantbutnotmaternaldiagnosisisassociatedwithincreasedanxietyinpreschoolers.”XVIIthBiennialInternationalConferenceonInfantStudies,Baltimore,MD,2010.

Sunanda Sukumar Sukumar,S.,Woo,B.,andSukumar,N.“DockingofDipeptidestoMetabotropicGlutamateReceptors.”NERMMeeting,June2008.

Elisabeth Vines Vines,E.DinnerPrepacceptedintojuriedFencesSelectExhibitattheArtsCenteroftheCapitalRegion,Summer2009.

PODIUM PRESENTATIONSKenneth Blume Blume,K.“ThatVoodooThatYouDo:JohnStephensDurham,CaribbeanCultures,andAfrican-AmericanRacialIdentities,1865-1914.”AmericanSocietyforEthnohistoryAnnualMeeting,NewOrleans,LA,October2009.

Margaret Carroll Carroll,M.“TheSocialProgramsofJohnMcCloskey.”TheAmericanConferenceforIrishStudiesNationalConference,Galway,Ireland,June,2009.

Carroll,M.“JohnMcCloskeyandthePopularPress.”ResearchingNewYork:PerspectivesonEmpireStateHistory,StateUniversityofNewYorkatAlbanyinpartnershipwiththeNewYorkStateArchives,Nov.19-20,2009.

Ray Chandrasekara Chandrasekara,R.“ChinainAfrica:ExpandingtheStrategicPeriphery.”35thAnnualConferenceofNewYorkAfricanStudiesAssociationatSUNY-Bingham-ton,March26-27,2010.

Paul Denvir Denvir,P.“SomedilemmaticaspectsofadvisingpatientstobetestedforHIVinprimarycarecontexts.”UniversityatAlbanyCommunicationResearchSeminar,2010.

Denvir,P.“Identitymanagementduringroutine‘lifestyle’historytaking:Practicesthatpatientsemploywhenreportingonproblematicconduct.”95thAnnualMeetingoftheNationalCommunicationAs-sociation,Chicago,2009.

Daniel d’Oney d’Oney,D.“Creoles,Indians,andSugarPrinces:InterpretationofHoumaIndianHistoryonLouisiana’sRiverRoad.ManyVoices—OneStory?”AConferenceonPublicHistoryNarrativesofNativeAmericanandAfricanAmericanHistories,Raleigh,NorthCarolina,April,2010.

d’Oney,D.“Fire,WaterandGovernmentKnowNoth-ingofMercy:CourtCasesWhichDeterminedHoumaIdentity.”AmericanSocietyforEthnohistoryConfer-ence,NewOrleans,Louisiana,October,2009.

Kevin Hickey Hickey,K.“‘Enfouiesdansleschairs’:EuropeanBody,AfricanBody,Identity.”35thAnnualNewYorkAfricanStudiesAssociation(NYASA)ConferenceonGlobal-Africa,Global-Asia:AfricaandAsiaintheAgeofGlobalization,SUNYBinghamton,March27,2010.

Hickey,K.“‘Toroofthesea’:DerekWalcott’sCaribbeanResponsetoKant’s‘UltimatePurposeofNature.’”36thAnnualAfricanLiteratureAssociation(ALA)Confer-enceonEco-Imagination:AfricanandDiasporanLiteraturesandSustainability,UniversityofArizona,Tucson,March13,2010.

Wendy Parker Parker,W.M.,Wilmoth,J.M.,andLondon,A.S.“DoesMilitaryServiceOffsettheEffectofChildhoodSESDisadvantageonMen’sLaterLifePhysicalFunction-ing?”AnnualmeetingoftheGerontologicalSocietyofAmerica(GSA),Atlanta,GA,November18-22,2009.

Parker,W.M.“ParentalResourcesandChildHealth:AnInitialExaminationofChildHealthTrajectories.”An-nualMeetingoftheAmericanSociologicalAssocia-tion,SanFrancisco,CA,August8-11,2009.

Michael Pittman Pittman,M.“G.I.GurdjieffandSufisminAmerica:Contribution,Confluence,andControversy.”Ameri-canAcademyofReligionConference,Montreal,CA,November9,2009.

Pittman,M.“G.I.GurdjieffandLate19thCentury/Early20thCenturyCosmopolitanismintheCaucasus.”AmericanComparativeLiteratureAssociationConfer-ence.NewOrleans,LA,April4,2010.

Michael Racz RaczMJ,SedranskJ.“Bayesianandfrequentistmethodsforproviderprofilingusingrisk-adjustedassessmentsofmedicaloutcomes.”8thInternationalConferenceonHealthPolicyStatistics,Washington,D.C.,January2010.

RaczMJ,SedranskJ.“Bayesianandfrequentistmethodsforproviderprofilingusingrisk-adjustedassessmentsofmedicaloutcomes.”JointStatisti-calMeetings,Vancouver,BritishColumbia,Canada,August2010.

Laura Rogers Rogers,L.“CollegeinPrison:RemixingPower,IdentityandResistance.”ConferenceonCollegeCompositionandCommunication,Louisville,KY,2009.

GRANTSSunanda Sukumar SPONSOR/GRANTTITLE:AmericanChemicalSociety/ProjectSEEDAwardTERM:06/01/10-07/31/10TOTALGRANT:$2,800.00

Scholarly Activity Report

Bolded nameswithincitationsindicateACPHSfacultycollaborators.

54

ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCESCabinet Members James J. Gozzo, Ph.D. President

Mehdi Boroujerdi, Pharm.D., Ph.D. Provost and Dean

Vicki DiLorenzo Vice President, Institutional Advancement

Angela Dominelli, Ph.D. Associate Vice President of Institutional Effectiveness

Tiffany Gutierrez Vice President, Enrollment Management

Gerald Katzman General Counsel

Packy McGraw Associate Vice President of Administrative Operations

Shaker Mousa, Ph.D. Vice Provost for Research and Chairman of PRI

Michael A. Sass Special Assistant to the President

Pamela Smith Chief Technology Officer, Information Technology Services

Michele Vien Vice President of Finance

ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES BOARD OF TRUSTEES 2010 - 2011OfficersAlfred J. Collins Jr. ‘53 Chairman

Herbert Chorbajian Vice Chair

Christopher Mitiguy Treasurer

Bridget-ann Hart ‘80 Secretary

Term TrusteesStephen C. Ainlay Robert S. BuschRichard H. Daffner ’63J. Gordon Dailey ‘57 Francis J. DiLascia ‘54Melvin Friedland ‘58Geno J. Germano ‘83Rocco F. Giruzzi, Jr. ‘58Zachary I. Hanan ’63Hugh A. JohnsonJeanette S. Lamb ’57Joseph M. LapetinaThomas O. MaggsFouad Morkos Marion T. Morton ‘84

Trustees Emeriti Michael F. BetteKenneth M. Nirenberg

“Progress is the activity of today and the assurance of tomorrow.”

55

“Progress is the activity of today and the assurance of tomorrow.” - Ralph Waldo Emerson

56

Non-Profit Org US PostagePAID Albany, NYPermit No. 349